



SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NOVEL ABCA10 TRANSPORTER AND USES THEREOF

BACKGROUND OF THE INVENTION

Field of the invention

- The invention relates generally to the field of an ATP Binding
- 5 Cassette (ABC) transporter family, and more specifically to a novel member of the family and the use thereof.

Description of the Related Art

- ABC transporter proteins represent a large superfamily of proteins with conserved features in both prokaryotes and eukaryotes. ABC transporters
- 10 catalyze ATP-dependent transport of endogenous or exogenous substrates across biological membranes (Borst, P., (1997) *Seminar in Cancer Biology* 8:131-213) and/or allosterically modify the function of heterologous proteins (Higgins CF, 1995, *Cell* 82:693-696). Several ABC transporters have been associated with clinically relevant phenotypes including the phenomenon of
- 15 multidrug resistance (Ambudkar S.V. *et al.*, (1999), *Annu. Rev. Toxicol.*, 39:361-398), cystic fibrosis (Riordin JR *et al.*, (1989) *Science* 245:1066-1073), atherosclerosis (Brooks-Wilson A *et al.*, (1999) *Nature Genetics* 22:336-345), hyperinsulinemic hypoglycemia (Thomas PM *et al.*, (1995) *Science* 268:46-429), macular degeneration (Allikmets R *et al.*, (1997) *Science* 277:1805-1807),
- 20 and adrenoleukodystrophy (Mosser J *et al.*, (1993) *Nature* 361:726-730) to name but a few. There is a need in the art for identification of the full-length nucleotide sequence of the coding region of the ABC transporter genes and translated protein products.

BRIEF SUMMARY OF THE INVENTION

- 25 The present invention is based, at least in part, on the discovery of a novel ATP Binding Cassette (ABC) transporter family member, referred to herein as ABCA10 transporter nucleic acid and protein molecules. The ABCA10 transporter molecules of the present invention are useful as targets for developing modulating agents to regulate a variety of cellular processes,
- 30 particularly the transport of neurotoxic molecules, e.g., β -amyloid peptide ($A\beta$), across cell membranes or, e.g., the blood-brain barrier (BBB). Neurotoxic molecules such as β -amyloid peptide are involved in neurological disorders

such as Alzheimer's disease (see, e.g., Goate *et al.* (1991) *Nature* 349:704; Games *et al.* (1995) *Nature* 373:523; and Suzuki *et al.* (1994) *Science* 264:1336). Other neurological diseases involving toxic polypeptides include, e.g., prion diseases, Huntington's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Spinocerebellar Ataxia, Frontotemporal Dementia, etc. (Hardy *et al.* (1998) *Science* 282:1075-1079; Wolozin *et al.* (2000) *Arch. Neurol.*, 57:793-796). Accordingly, modulation of amyloid- β protein export with a modulator of the human ABCA10 transporter would be expected to modulate amyloid deposition and thus, Alzheimer's disease. In addition, the ABCA10 transporter molecules of the invention are useful as targets for developing modulating agents of multidrug resistance. Moreover, the molecules of the present invention are useful as diagnostic and therapeutic tools.

Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding ABCA10 transporter proteins or functional fragments thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of ABCA10-encoding nucleic acids.

In one embodiment, the isolated nucleic acid comprises a nucleotide sequence that is at least 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or more identical to either a portion of, or the full length of, the nucleotide sequence.

In another embodiment, the isolated nucleic acid comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence at least about 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or more identical to either a portion of, or the full length of, the amino acid sequence of SEQ ID NO: 2 or 4.

In another embodiment, the isolated nucleic acid comprises a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO: 1 or 3 under stringent conditions.

In a preferred embodiment, the isolated nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO: 1 or 3.

In another preferred embodiment, the isolated nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4.

In yet another preferred embodiment, the nucleic acid molecule comprises a nucleotide sequence that encodes a naturally occurring allelic variant of the amino acid sequence set forth in SEQ ID NO: 2 or 4, wherein said allelic variant binds to an antibody that selectively binds to the polypeptide of
5 SEQ ID NO: 2 or 4.

In another aspect, the invention provides an oligonucleotide primer comprising at least 12 contiguous nucleotides of SEQ ID NO: 1 or 3, or a complement thereof from a region specific to ABCA10 transporters.

The invention also provides an isolated nucleic acid molecule
10 comprising a nucleotide sequence that is complementary to any one of the nucleic acid molecules described above.

In another aspect, the invention provides an isolated nucleic acid molecule comprising a nucleic acid molecule encoding an ABCA10 transporter or a functional fragment thereof described above and a nucleotide sequence
15 encoding a heterologous polypeptide.

Another aspect of the invention provides a vector comprising a nucleic acid molecule encoding an ABCA10 transporter or a functional fragment thereof described above. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell
20 containing a vector of the invention. In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing an ABCA10 transporter protein or a functional fragment thereof, by culturing in a suitable medium, a host cell of the invention containing a recombinant expression vector, such that the protein
25 is produced.

Another aspect of this invention features isolated or recombinant ABCA10 transporter polypeptides and functional fragments thereof. In one embodiment, the isolated polypeptide comprises the amino acid sequence of
30 SEQ ID NO: 2 or 4 or a functional fragment thereof. In another embodiment, the isolated polypeptide comprises a naturally occurring allelic variant of the amino acid sequence of SEQ ID NO: 2 or 4, wherein the allelic variant binds to an antibody that selectively binds to the polypeptide of SEQ ID NO: 2 or 4. In another embodiment, the isolated polypeptide comprises a functional fragment of the naturally occurring allelic variant described above. In another
35 embodiment, the isolated polypeptide comprises an amino acid sequence which is at least about 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%,

85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or more similar to the amino acid sequence of SEQ ID NO: 2 or 4. In yet another embodiment, the isolated polypeptide comprises a functional fragment of the polypeptide having a sequence similar to the amino acid sequence of
5 SEQ ID NO: 2 or 4 as described above.

In yet another embodiment, the polypeptide, preferably an ABCA10 transporter protein, is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:
10 1 or 3.

In another embodiment, the invention features an isolated protein, preferably an ABCA10 transporter protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
15 96%, 97%, 98%, or more identical to a nucleotide sequence of SEQ ID NO: 1 or 3.

The proteins of the present invention or portions thereof, *e.g.*, biologically active portions thereof, can be operatively linked to heterologous amino acid sequences (*e.g.*, a non-ABCA10 transporter polypeptide) at either
20 the amino- or the carboxyl- terminus of the proteins to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind proteins of the invention, preferably ABCA10 transporter proteins. In addition, the ABCA10 transporter proteins or functional fragments thereof can be incorporated into pharmaceutical compositions, which
25 optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides a method for detecting the presence of an ABCA10 polypeptide or a functional fragment thereof in a biological sample. The method comprises the following two steps: contacting the sample with a compound which selectively binds to the ABCA10
30 polypeptide or its functional fragment, and detecting the presence of a complex between the compound and the polypeptide or its functional fragment. In a preferred embodiment, the compound that binds to the polypeptide is an antibody. In addition, the invention also provides a kit comprising a compound that selectively binds to an ABCA10 polypeptide or a functional fragment
35 thereof and instructions for use.

In another aspect, the present invention provides a method for detecting the presence of a nucleic acid molecule encoding an ABCA10 transporter or a functional fragment thereof in a biological sample. The method comprises the following two steps: contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule, and detecting the presence of a complex of the nucleic acid molecule and the probe or primer. In one embodiment, the sample comprises mRNA molecules and is contacted with a nucleic acid probe. In addition, the present invention also provides a kit comprising a compound that selectively hybridizes to a nucleic acid molecule encoding an ABCA10 transporter or a functional fragment thereof and instructions for use.

The present invention also provides a method for identifying a compound that binds to an ABCA10 polypeptide or a functional fragment thereof. The method comprises the following two steps: contacting the polypeptide, the functional fragment, or a cell expressing the polypeptide or the functional fragment with a test compound; and determining whether the polypeptide binds to the test compound. The binding of the test compound to the polypeptide may be detected directly, or by a competitive binding assay or an assay for ABCA10 transporter activity.

The present invention further provides methods for modulating the activity of an ABCA10 polypeptide or a functional fragment thereof. One method comprises the following two steps: contacting the polypeptide, the functional fragment, or a cell expressing the polypeptide or its functional fragment with a compound that binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide. In one embodiment, the compound inhibits ABCA10 transporter activity. In another embodiment, the compound modulates the ability of the ABCA10 transporter to allosterically modify the function of other membrane proteins. In yet another embodiment, the compound stimulates ABCA10 transporter activity. In one embodiment, the compound is an antibody that specifically binds to an ABCA10 transporter protein.

Another method for modulating the activity of an ABCA10 polypeptide or a functional fragment thereof is to contact a cell capable of expressing an ABCA10 transporter with an agent that modulates ABCA10 transporter activity such that ABCA10 transporter activity in the cell is modulated. In one embodiment, the agent inhibits ABCA10 transporter activity.

In another embodiment, the agent modulates the ability of the ABCA10 transporter to allosterically modify the function of other membrane proteins. In another embodiment, the agent stimulates ABCA10 transporter activity. In one embodiment, the agent is an antibody that specifically binds to an ABCA10 transporter protein. In another embodiment, the agent modulates expression of ABCA10 transporter by modulating transcription of an ABCA10 transporter gene or translation of an ABCA10 transporter mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of an ABCA10 transporter mRNA or an ABCA10 transporter gene.

In one embodiment, the methods of the present invention are used to treat a subject having a disorder characterized by aberrant or unwanted ABCA10 transporter protein or nucleic acid expression or activity by administering an agent which is an ABCA10 transporter modulator to the subject. In one embodiment, the ABCA10 transporter modulator is an ABCA10 transporter protein. In another embodiment the ABCA10 transporter modulator is an ABCA10 transporter nucleic acid molecule. In yet another embodiment, the ABCA10 transporter modulator is a polypeptide antibody (or fragment thereof), peptide, peptidomimetic, or other small molecule, e.g., a molecule that is carbohydrate-based, lipid-based, nucleic acid-based, natural organic-based, or synthetically derived organic-based.

In another aspect, the present invention also provides a method for identifying a compound that modulates the activity of an ABCA10 polypeptide or a functional fragment thereof. The method comprises the following two steps: contacting an ABCA10 polypeptide or a functional fragment thereof with a test compound, and determining the effect of the test compound on the activity of the polypeptide or the functional fragment to thereby identify a compound which modulates the activity of the polypeptide or the functional fragment.

In another aspect, the present invention provides a method for detecting an allelic variation of the nucleic acid of SEQ ID NO: 1 or 3 or an orthologue thereof in a biological sample. The method comprises the following two steps: (a) obtaining from said sample a polynucleotide that hybridizes to the nucleic acid of SEQ ID NO: 1 or 3 or the orthologue thereof; and (b) determine whether the polynucleotide is identical to a portion, or the full length sequence, of SEQ ID NO: 1 or 3 or the orthologue thereof.

The present invention also provides a composition comprising a pharmaceutically effective amount of the nucleic acid molecule of SEQ ID NO: 1 or 3 or a functional fragment thereof and a pharmaceutically acceptable carrier. In a related aspect, the present invention provides a composition
5 comprising a pharmaceutically effective amount of an antisense oligonucleotide capable of specifically hybridizing to a portion, or the full length, of the nucleic acid sequence of SEQ ID NO: 1 or 3 or a functional fragment thereof and a pharmaceutical acceptable carrier.

In another aspect, the present invention provides a method for
10 detecting the presence of ABCA10 transporter activity in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of ABCA10 transporter activity such that the presence of ABCA10 transporter activity is detected in the biological sample.

The present invention also provides a diagnostic assay for
15 identifying the presence or absence of a genetic alteration characterized by at least one of (i) aberrant modification or mutation of a gene encoding an ABCA10 transporter protein; (ii) mis-regulation of the gene; and (iii) aberrant post-translational modification of an ABCA10 transporter protein, wherein a wild-type form of the gene encodes a protein with an ABCA10 transporter
20 activity.

In another aspect the invention provides a method for identifying a compound that binds to or modulates the activity of an ABCA10 transporter protein, by providing an indicator composition comprising an ABCA10 transporter protein having ABCA10 transporter activity, contacting the indicator
25 composition with a test compound, and determining the effect of the test compound on ABCA10 transporter activity in the indicator composition to identify a compound that modulates the activity of an ABCA10 transporter protein, e.g., an ABCA10 transporter protein associated with a membrane.

A further embodiment of the current invention provides a
30 transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous ABCA10 gene, wherein the homozygous disruption prevents the expression of a functional ABCA10 protein, and wherein the homozygous disruption results in the transgenic knockout mouse being sterile.

35 A further embodiment of the current invention provides a transgenic knockout mouse whose genome comprises a homozygous

disruption in its endogenous ABCA10 gene, wherein the homozygous disruption prevents the expression of a functional ABCA10 protein, and wherein the homozygous disruption results in the transgenic knockout mouse suffering from hypo- or hyperglycemia, compared to a wild-type mouse. A further embodiment of the current invention provides a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous ABCA10 gene, wherein the homozygous disruption prevents the expression of a functional ABCA10 protein, and wherein the homozygous disruption results in the transgenic knockout mouse suffering from muscular disorders, compared to a wildtype mouse.

A further embodiment of the current invention provides a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous ABCA10 gene, wherein the homozygous disruption prevents the expression of a functional ABCA10 protein, and wherein the homozygous disruption results in the transgenic knockout mouse suffering from cardiovascular disorders and/or coronary arteriosclerosis, compared to a wild-type mouse.

A further embodiment of the current invention provides a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous ABCA10 gene, wherein the homozygous disruption prevents the expression of a functional ABCA10 protein, and wherein the homozygous disruption results in the transgenic knockout mouse suffering from liver disorders, compared to a wild-type mouse.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the cDNA sequence of a human ABCA10 transporter. The nucleotide sequence is 5680 nucleotides in length, and is also represented by SEQ ID NO: 1.

Figure 2 depicts the amino acid sequence of the ABCA10 transporter molecule corresponding to amino acids 1 to 1529 which is represented by SEQ ID NO: 2.

Figure 3 depicts a summary view of ABCA10 translation, with a start codon at nucleotides 254-257 and a stop codon at nucleotides 4841-4843. An earlier stop codon at positions 65-67 precedes the open reading frame of ABCA10.

BRIEF DESCRIPTION OF THE SEQUENCE IDENTIFIERS

SEQ ID NO:1 depicts a cDNA sequence of the human ABCA10 transporter.

5 SEQ ID NO:2 depicts an amino acid sequence of the human ABCA10 transporter.

SEQ ID NO:3 depicts a cDNA sequence of the human ABCA10 transporter.

SEQ ID NO:4 depicts an amino acid sequence of the human ABCA10 transporter.

10 DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, at least in part, on the discovery of novel ATP Binding Cassette (ABC) transporter family members, referred to herein as ABCA10 transporter nucleic acid and protein molecules. ABC transporter molecules are transmembrane proteins that catalyze ATP-
15 dependent transport of endogenous or exogenous substrates across biological membranes. ABC transporters have been associated with the transport of polypeptides, *e.g.*, a neurotoxic polypeptide, such as β -amyloid, which is involved in Alzheimer's disease. Other neurological diseases caused by neurotoxic polypeptides include prion diseases, Parkinson's disease,
20 Huntington's disease, *etc.* (for a review, see Hardy *et al.* (1998) *Science* 282: 1075-1079). In particular, ABC transporters are associated with the transport of substrates across the blood-brain-barrier. In addition, ABC transporters are associated with multidrug resistance found in cells especially, *e.g.*, cells that are refractory to cytotoxic anti-cancer drugs (Borst, P. (1997) *Sem. Cancer Bio.*
25 8:131-134).

Accordingly, the ABCA10 transporter molecules of the invention are suitable targets for developing novel diagnostic targets and therapeutic agents to control cellular transport in cells of the brain (*e.g.*, neuronal cells) and transport across the blood-brain-barrier. Moreover, the ABCA10 transporter
30 molecules are suitable targets for developing diagnostic targets and therapeutic agents for detecting and/or treating cells or tissues having multidrug resistance, *e.g.*, a cancer.

In particular, the novel human ABCA10 transporter molecules described herein are believed to have one or more of the following functions
35 and/or applications:

First, ABC transporters expressed in the brain are implicated in the transport of substrates through the blood brain barrier (Schinkel A.H., *et al*, (1994) *Cell*, 77, 491) and therefore identification of the sequence of the human ABCA10 transporter described herein affords the development of new strategies for altering the function of the blood brain barrier. Given that many drugs of potential utility in treating diseases of the brain are discarded because they do not enter the brain at therapeutically relevant concentrations, the present invention allows for the development of strategies to assist in the delivery of drugs to the brain.

Second, ABC transporters expressed in the brain (as described in, e.g., U.S. Patent Application No. 08/847,616, the text of which is incorporated herein) are potential transporters for the β -amyloid peptide, a peptide whose deposition in senile plaques is a fundamental feature of Alzheimer's disease. Thus, identifying novel transporters that regulate β -amyloid deposition is crucial in developing therapeutic treatment for Alzheimer's disease.

Third, the human homologue of the *Drosophila melanogaster* white gene has been reported to be associated with mood and panic disorders (Nakamura M *et al*, (1999), *Mol. Psychiatry*, 4, 155-162), and this gene is a member of the superfamily of ABC transporters. Identification of the sequence of human ABC transporter described herein allows for the development of new treatments for mood and panic disorders.

Fourth, ABC transporters have been shown to be involved in the phenomenon of multidrug resistance (Ling, V., (1997) *Cancer Chemother Pharmacol* 40:S3-S8. The present invention will allow precise determination of the ability of ABCA10 to contribute to the multidrug resistance phenotype and the design of agents capable of ameliorating multidrug resistance using techniques similar to those described by Boer, R., *et al*. ((1996) *European Journal of Cancer*, 32A:857-861).

Fifth, the human ABC1 protein has been shown to be associated with cholesterol efflux and mutated forms cause Tangier disease and familial high-density lipoprotein deficiency (Brooks-Wilson A. *et al*, Bodzioch M. *et al*, Rust S. *et al*, *Nature Genetics*, 22, 336-345, 347-351, 352-355 respectively). As the ABC1 protein is a homologue of the ABCA10 protein, human ABCA10 may also be found to be a cholesterol transporter. Identification of the

sequence of human ABCA10 allows for the development of new treatments for diseases involving cholesterol misregulation.

Sixth, the mouse *abc1* protein has been implicated in interleukin-1 β (IL-1 β) secretion from macrophages (Hamon Y. *et al*, 1997, *Blood*, 90, 2911-2915). IL-1 β is a mediator of inflammatory reactions, and agents able to impair its production or secretion are of potential therapeutic importance. Thus, identification of the related sequence of human ABCA10 allows for the development of new treatments for inflammatory diseases.

The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin. Members of a family may also have common functional characteristics.

For example, the family of ABC transporter proteins comprise at least one "transmembrane domain" and preferably two transmembrane domains. As used herein, the term "transmembrane domain" includes an amino acid sequence of about 18 amino acid residues in length which spans the plasma membrane. More preferably, a transmembrane domain includes about at least 18, 20, 25, 30, 35, 40, or 45 residues or more and spans the plasma membrane. Transmembrane domains are described in, for example, Zagotta W.N. *et al*, (1996) *Annual Rev. Neurosci.* 19: 235-63, the contents of which are incorporated herein by reference. One or more of these transmembrane domains may associate to form a membrane-spanning domain.

Isolated proteins of the present invention, preferably ABCA10 transporter proteins or functional fragment thereof, have an amino acid sequence sufficiently homologous to the full length, or a portion, of the amino acid sequence of SEQ ID NO: 2 or 4 or are encoded by a nucleotide sequence sufficiently homologous to SEQ ID NO: 1 or 3. As used herein, the term "sufficiently homologous" in the context of amino acid sequences refers to an amino acid sequence that contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues relative to a reference amino acid or nucleotide sequence such

that the two sequences share common structural domains or motifs and/or a common functional activity. When used in the context of nucleotide sequences, this term refers to a nucleotide sequence a nucleotide sequence that contains a sufficient or minimum number of identical nucleotide residue relative to a reference nucleotide sequence. For example, sufficiently homologous amino acid sequences typically have at least 50% homology, more preferably 60%, even more preferably 70%-80%, and most preferably 90-95% or higher homology across the amino acid sequences of their shared common domains. Likewise, sufficiently homologous nucleotide sequences generally have at least 50%, more preferably 60%, even more preferably 70%-80%, and most preferably 90-95% or higher sequence identity.

As used interchangeably herein, "ABCA10 transporter activity," "biological activity of an ABCA10 transporter" or "functional activity of an ABCA10 transporter," refers to an activity exerted by an ABCA10 transporter protein, polypeptide or nucleic acid molecule on an ABCA10 transporter responsive cell or on an ABCA10 transporter protein substrate, as determined *in vivo*, or *in vitro*, according to standard techniques.

Preferably, an ABCA10 transporter activity has the ability to act as an energy-dependent (ATP) molecular pump. In one embodiment, an ABCA10 activity is a direct activity, such as an association with a membrane-associated protein and/or the transport of an endogenous or exogenous substrate across a biological membrane. In another embodiment, the ABCA10 activity is the ability of the polypeptide to allosterically modify the function of other membrane proteins. For example, in some cells, modulation of p-glycoprotein by an ABC transporter modulator has been shown to alter the magnitude of volume-activated chloride currents (reviewed in Higgins, C. F. Volume-activated chloride currents associated with the multidrug resistance P-glycoprotein, *J. Physiol.* 482:31S-36S (1995)). Thus, in this model, p-glycoprotein and other ABC transporters have multiple functions, one of which is to allosterically modify the function of the other membrane proteins.

The present invention is consistent with a model in which the allosteric modification of other membrane proteins by e.g., an ABCA10 transporter, is responsible for a change in the transport of a substrate, e.g., β -amyloid, a cytotoxic drug, or other small molecule. Accordingly, an ABCA10 activity is at least one or more of the following activities:

1. activation of an ABCA10-dependent signal transduction pathway;
2. modulation of the transport of a substrate (e.g., a cytotoxic drug, β -amyloid) across a membrane;
- 5 3. interaction of an ABCA10 protein with a non- ABCA10 membrane-associated molecule;
4. modulation of the development or differentiation of an ABCA10-expressing cell;
5. modulation of the development or differentiation of a non- ABCA10-expressing cell;
- 10 6. modulation of the homeostasis of an ABCA10-expressing cell;
7. modulation of the homeostasis of a non- ABCA10-expressing cell; and
8. binding to ATP.

15 As used herein, an "ABCA10 transporter" (also referred to as "ABCA10 protein" or "ABCA10 polypeptide") is a polypeptide having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 97% sequence identity with the full length sequence of human ABCA10 transporter (SEQ ID NO: 2 or 4) and having at least one of the above functions. A "functional fragment" (also
20 referred to as "biologically active portion") refers to a portion of an ABCA10 transporter having at least one of the above functions.

Various aspects of the invention are described in further detail in the following subsections. The contents of all patents, patent applications, and references cited throughout the application are hereby incorporated by
25 reference in their entireties.

A. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode ABCA10 transporter proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as
30 hybridization probes to identify ABCA10-encoding nucleic acid molecules (e.g., ABCA10 transporter mRNA) and fragments for use as PCR primers for the amplification or mutation of ABCA10 transporter nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and
35 analogs of the DNA or RNA generated using nucleotide analogs. The nucleic

acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term "isolated nucleic acid molecule" includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated" includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated ABCA10 transporter nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 or 3, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequence of SEQ ID NO: 1 or 3 as a hybridization probe, ABCA10 transporter nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO: 1 or 3 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO: 1 or 3.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides

corresponding to ABCA10 transporter nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 1 or 3.

5 The sequence of SEQ ID NO: 1 or 3 corresponds to the human ABCA10 cDNA. This cDNA comprises sequences encoding the human ABCA10 protein (*i.e.*, "the coding region", from nucleotides 144-5018), as well as 5' untranslated sequences (nucleotides 1-143). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO: 1 (*e.g.*, nucleotides 144-5018,

10 corresponding to SEQ ID NO: 3).

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO: 1 or 3, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is

15 complementary to the nucleotide sequence shown in SEQ ID NO: 1 or 3 is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 1 or 3 such that it can hybridize to the nucleotide sequence shown in SEQ ID NO: 1 or 3, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at

20 least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or more identical to the entire length of the nucleotide sequence shown in SEQ ID NO: 1 or 3, or a portion of any of these nucleotide sequences. The identity algorithms and

25 settings that may be used includes computer programs which employ the Smith-Waterman algorithm, such as the MPSRCH program (Oxford Molecular), using an affine gap search with the following parameters: a gap open penalty of 12 and a gap extension penalty of 1. Preferably, GCG PileUp program (Genetics Computer Group, Madison, Wisconsin) (Gapweight: 4, Gaplength

30 weight: 1) is used for sequence alignment. Alternatively, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.

35 Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO: 1 or 3, for example,

a fragment which can be used as a probe or primer or a fragment encoding a portion of an ABCA10 transporter protein, *e.g.*, a biologically active portion of an ABCA10 transporter protein. The nucleotide sequence determined from the cloning of the ABCA10 transporter gene allows for the generation of probes and primers designed for use in identifying and/or cloning other ABCA10 transporter family members, as well as ABCA10 transporter homologues from other species (also referred to as "ABCA10 orthologues"). The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of an ABCA10 transporter gene (*e.g.*, SEQ ID NO: 1 or 3), of an anti-sense sequence of an ABCA10 transporter gene, or of a naturally occurring allelic variant or mutant of a wild type ABCA10 gene. The term "wild type ABCA10 transporter gene," as used herein, refers to an ABCA10 transporter gene present in the majority individual organisms of a selected population. In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is greater than 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500-1000, 1000-1500, 1500-2000, or 2000-2500 or more nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 1 or 3. In another exemplary embodiment, a nucleic acid molecule of the present invention comprises at least 12 contiguous nucleotides of SEQ ID NO: 1 or 3, or a complement thereof from a region specific to ABCA10 transporters. A "region specific to ABCA10 transporters," as used herein, includes 5'- and 3'- untranslated regions of an ABCA10 transporter gene, and coding regions encoding ABCA10-specific amino acid sequences that have less than 50%, preferably 40%, 30%, 20%, 10%, or 5% sequence homology with any region of the other ABC transporters.

Probes based on the ABCA10 transporter nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress an ABCA10 transporter protein, such as by measuring a level of an ABCA10-encoding nucleic acid in a sample of cells from a subject *e.g.*,

detecting ABCA10 transporter mRNA levels or determining whether a genomic ABCA10 transporter gene has been mutated or deleted.

A nucleic acid fragment encoding a "biologically active portion of an ABCA10 transporter protein" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO: 1 or 3 which encodes a polypeptide having an ABCA10 transporter biological activity (the biological activities of the ABCA10 transporter proteins are described herein), expressing the encoded portion of the ABCA10 transporter protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the ABCA10 transporter protein.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO: 1 or 3 due to degeneracy of the genetic code and thus encode the same ABCA10 transporter protein (i.e., SEQ ID NO: 2 or 4) as those encoded by the nucleotide sequence shown in SEQ ID NO: 1 or 3.

In addition to the ABCA10 transporter nucleotide sequences shown in SEQ ID NO: 1 or 3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the ABCA10 transporter proteins may exist within a population (e.g., the human population). Such genetic polymorphism in the ABCA10 transporter genes may exist among individuals within a population due to natural allelic variation. As used herein, the term "ABCA10 gene" refers to a nucleic acid molecule which includes an open reading frame encoding an ABCA10 transporter protein, preferably a mammalian ABCA10 transporter protein, and can further include non-coding regulatory sequences, and introns.

The present invention also provides nucleic acids encoding a polypeptide comprising a naturally occurring allelic variant of an ABCA10 transporter. As used herein, a "naturally occurring allelic variant of an ABCA10 transporter" refers to a polypeptide that is encoded by a nucleic acid having the same chromosomal location as a wild type ABCA10 transporter gene, exists in nature, and is sufficiently homologous with a wild type ABCA10 transporter protein. Typically, an allelic variant of an ABCA10 transporter binds to an antibody that selectively binds to the polypeptide of SEQ ID NO: 2 or 4.

Allelic variants of a human ABCA10 transporter include both functional and non-functional ABCA10 transporter proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the human

ABCA10 transporter that maintain the ability to bind an ABCA10 transporter ligand. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO: 2 or 4 or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein.

5 Non-functional allelic variants are naturally occurring amino acid sequence variants of the human ABCA10 transporter protein that do not have the ability to either bind an ABCA10 transporter ligand. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID NO: 2
10 or 4 or a substitution, insertion or deletion in critical residues or critical regions.

The present invention further provides nucleic acid sequences encoding non-human orthologues of the human ABCA10 transporter protein. Orthologues of the human ABCA10 transporter protein are proteins that are isolated from non-human organisms, have sequences more homologous to
15 human ABCA10 transporter protein than to the other human ABC transporter proteins, and possess functions similar to those of the human ABCA10 transporter protein.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the ABCA10 transporter cDNAs (including orthologues of
20 human ABCA10 transporter gene) of the invention can be isolated based on their homology to the ABCA10 transporter nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and
25 homologues of the ABCA10 transporter cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the ABCA10 transporter gene.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length
30 and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3. In other embodiment, the nucleic acid is at least 30, 50, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5447 or more nucleotides in length. As used herein, the term "hybridizes under
35 stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 75% homologous to each

other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 80%, even more preferably at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°C, and even more preferably at 65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1 or 3 corresponds to a naturally-occurring nucleic acid molecule.

In addition to naturally-occurring allelic variants of the ABCA10 transporter sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 1 or 3, thereby leading to changes in the amino acid sequence of the encoded ABCA10 transporter proteins, without altering the functional ability of the ABCA10 transporter proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: 1 or 3. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of ABCA10 transporter (e.g., the sequence of SEQ ID NO: 2 or 4) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding ABCA10 transporter proteins that contain changes in amino acid residues that are not essential for activity. Such ABCA10 transporter proteins differ in amino acid sequence from SEQ ID NO: 2 or 4, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or more homologous to SEQ ID NO: 2 or 4.

An isolated nucleic acid molecule encoding an ABCA10 transporter protein homologous to the protein of SEQ ID NO: 2 or 4 can be

created by introducing one or more nucleotide substitutions, additions, or deletions into the nucleotide sequence of SEQ ID NO: 1 or 3, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO: 1 or 3 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an ABCA10 transporter protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an ABCA10 transporter coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for ABCA10 transporter biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO: 1 or 3 the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant ABCA10 transporter protein can be assayed for the ability to interact with a non-ABCA10 transporter molecule, e.g., an ABCA10 transporter ligand, e.g., a polypeptide or a small molecule.

In addition to the nucleic acid molecules encoding ABCA10 transporter proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a

sense nucleic acid. The antisense nucleic acid can be complementary to an entire ABCA10 transporter coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding ABCA10. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the coding region of human ABCA10 corresponds to nucleotides 254-4840 of SEQ ID NO:1 or 3). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding ABCA10. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding ABCA10 transporter disclosed herein (e.g., Figure 3), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of ABCA10 transporter mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of ABCA10 transporter mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of ABCA10 transporter mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides or more in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-

5 methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, 10 queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been 10 subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or 15 bind to cellular mRNA and/or genomic DNA encoding an ABCA10 transporter protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through 20 specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules 25 can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular 30 concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic 35 acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other

(Gaultier *et al.* (1987) *Nucleic Acids. Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

5 In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach
10 (1988) *Nature* 334:585-591)) can be used to catalytically cleave ABCA10 transporter mRNA transcripts to thereby inhibit translation of ABCA10 transporter mRNA. A ribozyme having specificity for an ABCA10-encoding nucleic acid can be designed based upon the nucleotide sequence of an ABCA10 transporter cDNA disclosed herein (*i.e.*, SEQ ID NO: 1 or 3). For
15 example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an ABCA10-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, ABCA10 transporter mRNA can be used to select a
20 catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, ABCA10 transporter gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory
25 region of the ABCA10 transporter (*e.g.*, the ABCA10 transporter promoter and/or enhancers) to form triple helical structures that prevent transcription of the ABCA10 transporter gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

30 In yet another embodiment, the ABCA10 transporter nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids
35 (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4 (1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid

mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.

- 5 The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *et al.* *Proc. Natl. Acad. Sci.* 93: 14670-675.

PNAs of ABCA10 transporter nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as
10 antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of ABCA10 transporter nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in
15 combination with other enzymes, (e.g., S1 nucleases (Hyrup B. (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *supra*).

In another embodiment, PNAs of ABCA10 transporter nucleic acid molecules can be modified, (e.g., to enhance their stability or cellular uptake),
20 by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of ABCA10 transporter nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA
25 recognition enzymes, (e.g., RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) *supra*). The synthesis of PNA-
30 DNA chimeras can be performed as described in Hyrup B. (1996) *supra* and Finn P.J. *et al.* (1996) *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a
35 between the PNA and the 5' end of DNA (Mag, M. *et al.* (1989) *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to

produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.* (1996) *supra*). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

- 5 In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, *e.g.*, Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents (See, *e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (*e.g.*, a
- 10 peptide, hybridization triggered cross-linking agent, transport agent, or
- 15 hybridization-triggered cleavage agent).

B. Isolated ABCA10 transporter proteins and Anti-ABCA10 transporter Antibodies

- One aspect of the invention pertains to isolated ABCA10
- 20 transporter proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-ABCA10 transporter antibodies. In one embodiment, the isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or 4 or a functional fragment thereof. In another embodiment, the isolated polypeptide comprises a naturally
- 25 occurring allelic variant of the amino acid sequence of SEQ ID NO: 2 or 4. Typically, the allelic variant binds to an antibody that selectively binds to the polypeptide of SEQ ID NO: 2 or 4. In another embodiment, the isolated polypeptide comprises a functional fragment of the naturally occurring allelic variant described above. In another embodiment, the isolated polypeptide
- 30 comprises an amino acid sequence which is at least about 50%, 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or more similar to the amino acid sequence of SEQ ID NO: 2 or 4. In yet another embodiment, the isolated polypeptide comprises a functional fragment of the polypeptide having a

sequence similar to the amino acid sequence of SEQ ID NO: 2 or 4 as described above.

Native ABCA10 transporter proteins or functional fragments thereof of the present invention can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. Alternatively, ABCA10 transporter proteins or functional fragments thereof are produced by recombinant DNA techniques. In addition, an ABCA10 transporter protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

10 An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the ABCA10 transporter protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of ABCA10 transporter protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of ABCA10 transporter protein having less than about 30% (by dry weight) of non-ABCA10 transporter protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-ABCA10 transporter protein, still more preferably less than about 10% of non-ABCA10 transporter protein, and most preferably less than about 5% non-ABCA10 transporter protein. When the ABCA10 transporter protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of ABCA10 transporter protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of ABCA10 transporter protein having less than about 30% (by dry weight) of chemical precursors or non-ABCA10 transporter chemicals, more preferably less than about 20% chemical precursors or non-ABCA10 transporter chemicals, still more preferably less than about 10% chemical

precursors or non-ABCA10 transporter chemicals, and most preferably less than about 5% chemical precursors or non-ABCA10 transporter chemicals.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 70%, preferably, 80%, 90% or 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

A comparison of sequences and determination of percent identity and/or similarity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using standard art recognized comparison software using standard parameter settings. For example, the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>) can be employed using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public

databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to ABCA10 transporter nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to ABCA10 transporter protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

The present invention provides polypeptides comprising a functional fragment (also referred to as "a biologically active portion") of an ABCA10 transporter protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the ABCA10 transporter protein. A biologically active portion of an ABCA10 transporter protein can be a polypeptide which is, for example, 10, 25, 50, 100, 200, 300, 400, 500, 600, 700, 800 or more amino acids in length. In one embodiment, a biologically active portion of an ABCA10 transporter protein comprises at least one transmembrane domain. In another embodiment, biologically active portion of an ABCA10 transporter protein contains at least two transmembrane domains. One or more of these transmembrane domains may associate to form a membrane-spanning domain. In addition, or alternatively, the biologically active portion of the ABCA10 transporter protein may include multiple clusters of conserved residues that define an ATP binding domain. In addition, or alternatively, the biologically active portion of the ABCA10 transporter protein may comprise a Walker domain, e.g., a Walker A and/or Walker B domain (see Fig. 2.; Patel *et al.* (1998) *Trends Cell Biol* 8: 65-71). In a preferred embodiment, the biological active portion of the ABCA10 transporter protein participates in an interaction between an ABCA10 transporter molecule and a non-ABCA10 transporter molecule. Identification of these domains may be facilitated using any of a number of art recognized molecular modeling techniques as described herein. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant

techniques and evaluated for one or more of the functional activities of a native ABCA10 transporter protein. The identified biologically active portions can be used as targets for developing agents which modulate an ABCA10 transporter mediated activity.

5 The invention also provides ABCA10 transporter chimeric or fusion proteins. As used herein, an ABCA10 transporter "chimeric protein" or "fusion protein" comprises an ABCA10 transporter polypeptide or a functional fragment thereof operatively linked to a heterologous polypeptide. A "heterologous polypeptide" refers to a polypeptide that is not a portion of the full
10 length ABCA10 transporter at least a portion of which is fused to the heterologous polypeptide. Thus, the fusion protein of the present invention may comprise a portion of an ABCA10 transporter (e.g., a human ABCA10 transporter) and a portion of another ABCA10 transporter (e.g., a mouse ABCA10 transporter). In a preferred embodiment, an ABCA10 transporter
15 fusion protein comprises at least one biologically active portion of an ABCA10 transporter protein. In another preferred embodiment, an ABCA10 transporter fusion protein comprises at least two biologically active portions of an ABCA10 transporter protein. In yet another preferred embodiment, an ABCA10 transporter fusion protein comprises a non-ABCA10 transporter polypeptide. A
20 "non-ABCA10 transporter polypeptide," as used herein, refers to a polypeptide having an amino acid sequence having an amino acid sequence corresponding to a protein which is not sufficiently homologous to the ABCA10 transporter protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the ABCA10 transporter polypeptide and the non-ABCA10
25 transporter polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of an ABCA10 transporter polypeptide or a functional fragment thereof.

 In one embodiment, the fusion protein is a GST-ABCA10 transporter fusion protein in which the ABCA10 transporter sequences are
30 fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant ABCA10.

 In another embodiment, the fusion protein is an ABCA10 transporter protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of
35 ABCA10 transporter can be increased through use of a heterologous signal sequence.

The ABCA10 transporter fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The ABCA10 transporter fusion proteins can be used to affect the bioavailability of an ABCA10 transporter substrate. Use of ABCA10 transporter fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding an ABCA10 transporter protein; (ii) mis-regulation of the ABCA10 transporter gene; and (iii) aberrant post-translational modification of an ABCA10 transporter protein.

Moreover, the ABCA10-fusion proteins of the invention can be used as immunogens to produce anti-ABCA10 transporter antibodies in a subject, to purify ABCA10 transporter ligands and in screening assays to identify molecules which inhibit the interaction of an ABCA10 transporter with an ABCA10 transporter substrate.

Preferably, an ABCA10 transporter chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An ABCA10 transporter-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the ABCA10 transporter protein.

The present invention also pertains to variants of the ABCA10 transporter proteins which function as either ABCA10 transporter agonists or as ABCA10 transporter antagonists. Variants of the ABCA10 transporter proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of

an ABCA10 transporter protein. An agonist of the ABCA10 transporter proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of an ABCA10 transporter protein. An antagonist of an ABCA10 transporter protein can inhibit one or more of the activities of the naturally occurring form of the ABCA10 transporter protein by, for example, competitively modulating an activity of an ABCA10 transporter protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the ABCA10 transporter protein.

In one embodiment, variants of an ABCA10 transporter protein which function as either ABCA10 transporter agonists (mimetics) or as ABCA10 transporter antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of an ABCA10 transporter protein for ABCA10 transporter protein agonist or antagonist activity. In one embodiment, a variegated library of ABCA10 transporter variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of ABCA10 transporter variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential ABCA10 transporter sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of ABCA10 transporter sequences therein. There are a variety of methods which can be used to produce libraries of potential ABCA10 transporter variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential ABCA10 transporter sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.

In addition, libraries of fragments of an ABCA10 transporter protein coding sequence can be used to generate a variegated population of

ABCA10 transporter fragments for screening and subsequent selection of variants of an ABCA10 transporter protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an ABCA10 transporter coding sequence with a nuclease
5 under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an
10 expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the ABCA10 transporter protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and
15 for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of ABCA10 transporter proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene
20 library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of
25 functional mutants in the libraries, can be used in combination with the screening assays to identify ABCA10 transporter variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

An isolated ABCA10 transporter protein, or a portion or fragment
30 thereof, can be used as an immunogen to generate antibodies that bind ABCA10 transporter using standard techniques for polyclonal and monoclonal antibody preparation. A full-length ABCA10 transporter protein can be used or, alternatively, the invention provides antigenic peptide fragments of ABCA10 transporter for use as immunogens. Preferred epitopes encompassed by the
35 antigenic peptide are regions of ABCA10 transporter that are located on the

surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity. Other preferred epitopes are ABCA10 transporter-specific regions.

An ABCA10 transporter immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed ABCA10 transporter protein or a chemically synthesized ABCA10 transporter polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic ABCA10 transporter preparation induces a polyclonal anti-ABCA10 transporter antibody response.

Accordingly, another aspect of the invention pertains to anti-ABCA10 transporter antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as ABCA10 transporter. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind ABCA10 transporter. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of ABCA10 transporter. A monoclonal antibody composition thus typically displays a single binding affinity for a particular ABCA10 transporter protein with which it immunoreacts.

Polyclonal anti-ABCA10 transporter antibodies can be prepared as described above by immunizing a suitable subject with an ABCA10 transporter immunogen. The anti-ABCA10 transporter antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized ABCA10 transporter. If desired, the antibody molecules directed against ABCA10 transporter can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-ABCA10 transporter antibody titers are

highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad. Sci. USA* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an ABCA10 transporter immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds ABCA10 transporter.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-ABCA10 transporter monoclonal antibody (see, e.g., G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al.* *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse

splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind ABCA10, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-ABCA10 transporter antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with ABCA10 transporter to thereby isolate immunoglobulin library members that bind ABCA10. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT International Publication No. WO 92/18619; Dower *et al.* PCT International Publication No. WO 91/17271; Winter *et al.* PCT International Publication WO 92/20791; Markland *et al.* PCT International Publication No. WO 92/15679; Breitling *et al.* PCT International Publication WO 93/01288; McCafferty *et al.* PCT International Publication No. WO 92/01047; Garrard *et al.* PCT International Publication No. WO 92/09690; Ladner *et al.* PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

Additionally, recombinant anti-ABCA10 transporter antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such

chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.* International Application No. PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT International Publication No. WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

An anti-ABCA10 transporter antibody (e.g., monoclonal antibody) can be used to isolate ABCA10 transporter by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-ABCA10 transporter antibody can facilitate the purification of natural ABCA10 transporter from cells and of recombinantly produced ABCA10 transporter expressed in host cells. Moreover, an anti-ABCA10 transporter antibody can be used to detect ABCA10 transporter protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the ABCA10 transporter protein. Anti-ABCA10 transporter antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride

or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S , ^{33}P , ^{32}P , or ^3H .

5 C. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an ABCA10 transporter protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it
10 has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors
15 having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such
20 vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression
25 vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include
30 one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the
35 nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a

host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990).
5 Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art
10 that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g.,
15 ABCA10 transporter proteins, mutant forms of ABCA10 transporter proteins, fusion proteins, and the like).

The recombinant expression vectors of the invention can be designed for expression of ABCA10 transporter proteins in prokaryotic or eukaryotic cells. For example, ABCA10 transporter proteins can be expressed
20 in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using
25 T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino
30 terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion
35 expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the

fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in ABCA10 transporter activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for ABCA10 transporter proteins, for example. In a preferred embodiment, an ABCA10 transporter fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the ABCA10 transporter expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz
5 *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (Invitrogen Corp, San Diego, CA).

Alternatively, ABCA10 transporter proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9 cells) include the
10 pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987)
15 *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic
20 and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression
25 vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in
30 particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA*
35 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey

promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to ABCA10 transporter mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which an ABCA10 transporter nucleic acid molecule of the invention is introduced, *e.g.*, an ABCA10 transporter nucleic acid molecule within a recombinant expression vector or an ABCA10 transporter nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, an ABCA10 transporter protein can be expressed in bacterial cells

such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)*, and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an ABCA10 transporter protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) an ABCA10 transporter protein. Accordingly, the invention further provides methods for producing an ABCA10 transporter protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding an ABCA10 transporter protein has been introduced) in a suitable medium such that an ABCA10 transporter protein is produced. In another embodiment, the method further comprises isolating an ABCA10 transporter protein from the medium or the host cell.

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which ABCA10-coding sequences have been introduced. Such host cells can then be used to

5 create non-human transgenic animals in which exogenous ABCA10 transporter sequences have been introduced into their genome or homologous recombinant animals in which endogenous ABCA10 transporter sequences have been altered. Such animals are useful for studying the function and/or activity of an ABCA10 transporter and for identifying and/or evaluating

10 modulators of ABCA10 transporter activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A

15 transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a

20 mammal, more preferably a mouse, in which an endogenous ABCA10 transporter gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

25 A transgenic animal of the invention can be created by introducing an ABCA10-encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The ABCA10 transporter cDNA sequence of SEQ ID NO: 1 can be introduced as a transgene into the genome

30 of a non-human animal. Alternatively, a nonhuman homologue of a human ABCA10 transporter gene, such as a mouse or rat ABCA10 transporter gene, can be used as a transgene. Alternatively, an ABCA10 transporter gene homologue, such as another ABC transporter family member, can be isolated based on hybridization to the ABCA10 transporter cDNA sequences of SEQ ID

35 NO: 1 (described further in subsection I above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the

transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to an ABCA10 transporter transgene to direct expression of an ABCA10 transporter protein to particular cells. Methods for generating transgenic animals via embryo
5 manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar
10 methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of an ABCA10 transporter transgene in its genome and/or expression of ABCA10 transporter mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover,
15 transgenic animals carrying a transgene encoding an ABCA10 transporter protein can further be bred to other transgenic animals carrying other transgenes, for example, animals carrying a transgene encoding a neurotoxic polypeptide such as β -amyloid.

To create a homologous recombinant animal, a vector is prepared
20 which contains at least a portion of an ABCA10 transporter gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the ABCA10 transporter gene. The ABCA10 transporter gene can be a human gene, but more preferably, is a non-human homologue of a human ABCA10 transporter gene (*e.g.*, a cDNA isolated by stringent
25 hybridization with the nucleotide sequence of SEQ ID NO: 1). For example, a mouse ABCA10 transporter gene can be used to construct a homologous recombination nucleic acid molecule, *e.g.*, a vector, suitable for altering an endogenous ABCA10 transporter gene in the mouse genome. In a preferred embodiment, the homologous recombination nucleic acid molecule is designed
30 such that, upon homologous recombination, the endogenous ABCA10 transporter gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the homologous recombination nucleic acid molecule can be designed such that, upon homologous recombination, the endogenous ABCA10 transporter gene is
35 mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the

endogenous ABCA10 transporter protein). In the homologous recombination nucleic acid molecule, the altered portion of the ABCA10 transporter gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the ABCA10 transporter gene to allow for homologous recombination to occur between the
5 exogenous ABCA10 transporter gene carried by the homologous recombination nucleic acid molecule and an endogenous ABCA10 transporter gene in a cell, e.g., an embryonic stem cell. The additional flanking ABCA10 transporter nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of
10 flanking DNA (both at the 5' and 3' ends) are included in the homologous recombination nucleic acid molecule (see, e.g., Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The homologous recombination nucleic acid molecule is introduced into a cell, e.g., an embryonic stem cell line (e.g., by electroporation) and cells in which the
15 introduced ABCA10 transporter gene has homologously recombined with the endogenous ABCA10 transporter gene are selected (see e.g., Li, E. *et al.* (1992) *Cell* 69:915). The selected cells can then be injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then
20 be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of
25 the transgene. Methods for constructing homologous recombination nucleic acid molecules, e.g., vectors, or homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec *et al.*; WO 91/01140 by Smithies *et al.*; WO 92/0968 by Zijlstra *et al.*; and WO
30 93/04169 by Berns *et al.*

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase
35 system, see, e.g., Lakso *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of

Saccharomyces cerevisiae (O'Gorman *et al.* (1991) *Science* 251:1351-1355). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, *e.g.*, a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, *e.g.*, the somatic cell, is isolated.

The DNA sequences described herein (*e.g.*, SEQ ID NOs:1 and 3) can also be used to introduce a desired ABC transporter nucleotide sequence within a predicted location of the targeted genome, leading to the replacement of a copy of the targeted by another copy sufficiently homologous to allow a homologous recombination event to occur (knock-in homologous recombination). A knock-in of a target gene means an alteration in a host cell genome that results in altered expression, such as increased expression of the target gene, for example by the introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous copy of the target gene. See for example, U.S. Patent Nos. 6,335,180 and 6,194,633.

D. Pharmaceutical Compositions

The ABCA10 transporter nucleic acid molecules, portions of ABCA10 transporter genes encoding function fragments of ABCA10, fragments of ABCA10 transporter proteins, anti-ABCA10 transporter antibodies (also referred to herein as "active compounds"), antisense oligonucleotides capable

of specifically hybridizing to a portion, or the full length of, ABCA10 genes, or any compound identified as a modulator of an ABCA10 transporter (as described herein) can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved

against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

15 Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a fragment of an ABCA10 transporter protein or an anti-ABCA10 transporter antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic ABCA10 transporter dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

25 Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a

disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

5 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or
10 transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through
15 the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other
20 glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers
25 can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with
30 monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of
35 dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a

predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The

pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, 5 e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

E. Uses and Methods of the Invention

10 The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic).

15 The isolated nucleic acid molecules of the invention can be used, for example, to express ABCA10 transporter protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect ABCA10 transporter mRNA (e.g., in a biological sample) or a genetic alteration in an ABCA10 transporter gene, and to modulate ABCA10 transporter activity, as 20 described further below. The ABCA10 transporter proteins can be used to treat disorders characterized by insufficient or excessive production of an ABCA10 transporter substrate or production of ABCA10 transporter inhibitors. In addition, the ABCA10 transporter proteins can be used to screen for naturally occurring ABCA10 transporter substrates, to screen for drugs or compounds 25 which modulate ABCA10 transporter activity, as well as to treat disorders characterized by insufficient or excessive production of ABCA10 transporter protein or production of ABCA10 transporter protein forms which have decreased, aberrant or unwanted activity compared to ABCA10 transporter wild type protein. Moreover, the anti-ABCA10 transporter antibodies of the invention 30 can be used to detect and isolate ABCA10 transporter proteins, regulate the bioavailability of ABCA10 transporter proteins, and modulate ABCA10 transporter activity.

1. Screening Assays:

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents which bind to ABCA10 transporter proteins, have a stimulatory or inhibitory effect on, for example, ABCA10 transporter expression or ABCA10 transporter activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of an ABCA10 transporter substrate. Such modulators may be peptides, peptidomimetics, small molecules or other drugs.

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of an ABCA10 transporter protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of an ABCA10 transporter protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc.*

Natl. Acad. Sci. 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*).

In one embodiment, an assay is a cell-based assay in which a cell which expresses an ABCA10 transporter protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate ABCA10 transporter activity is determined. Determining the ability of the test compound to modulate ABCA10 transporter activity can be accomplished by monitoring, for example, cellular transport of organic anions, organic cations, cytotoxic anti-cancer drugs, intracellular calcium, potassium, phosphatidylcholine, sodium concentration, neuronal membrane depolarization, a neurotoxic polypeptide (e.g., β -amyloid), or the activity of an ABCA10 transporter-regulated transcription factor. The cell, for example, can be of mammalian origin, e.g., a neuronal cell. The ability of the test compound to modulate ABCA10 transporter binding to a substrate or to bind to ABCA10 transporter can also be determined. Determining the ability of the test compound to modulate ABCA10 transporter binding to a substrate can be accomplished, for example, by coupling the ABCA10 transporter substrate with a radioisotope or enzymatic label such that binding of the ABCA10 transporter substrate to ABCA10 transporter can be determined by detecting the labeled ABCA10 transporter substrate in a complex. Determining the ability of the test compound to bind ABCA10 transporter can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to ABCA10 transporter can be determined by detecting the labeled ABCA10 transporter compound in a complex. For example, compounds (e.g., ABCA10 transporter substrates) can be labeled with ^{125}I , ^{35}S , ^{14}C , ^{33}P , ^{32}P , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In one embodiment, suitable compounds include, but are not limited to, verapamil, desmethoxyverapamil, chloroquine, quinine, chinchonidine, primaquine, tamoxifen, dihydrocyclosporin, yohimbine, corynanthine, reserpine, physostigmine, acridine, acridine orange, quinacrine, trifluoroperazine, chlorpromazine, propranolol, atropine, tryptamine, forskolin, 1,9-dideoxyforskolin, cyclosporin, (US Patent 4,117,118 (1978)), PSC-833

- (cyclosporin D, 6-[(2S, 4R, 6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-(9CI)), [US Patent 5,525,590] [ACS 121584-18-7], Keller *et al.*, "SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming p-glycoprotein-mediated multidrug resistance of murine leukemia", *Int J Cancer* 50:593-597 (1992)), RU-486 (17 β -hydroxy-11 β -[4-dimethylaminophenyl]-17 α prop-1-ynyl estro-4, 9-dien-3 one), RU-49953 (17 β -hydroxy-11 β , 17 α -[4-dimethylaminophenyl] - 17 α prop-1-ynyl estro-4, 9 dien-3 one), S9778 (6-{4-[2,2-di()-ethylamino]-1-piperidinyl}-N,N', di-2-propenyl-1,3,5-triazine-2,4-diamine, bismethane sulfonate, [US patent 5,225,411; EP 466586] [ACS # 140945-01-3]; Dhainaut *et al.*, "New triazine derivatives as potent modulators of multidrug resistance," *J Medicinal Chemistry* 35:2481-2496 (1992)), MS-209 (5-[3-[4-(2,2-diphenylacetyl)piperazin-1-yl]-2-hydroxypropoxy]quinoline sesquifumarate, [US patent 5,405,843 (continuation of 5,112,817)], [ACS # 158681-49-3], Sato *et al.*, "Reversal of multidrug resistance by a novel quinoline derivative, MS-209, *Cancer Chemother Pharmacol* 35:271-277 (1995)), MS-073 (Fukazawa *et al.*, European Patent Application 0363212 (1989)), FK-506 (Tanaka *et al.*, M. Physicochemical properties of FK-506, a novel immunosuppressant isolated from *Streptomyces tsukubaensis*" *Transplantation Proceedings*. 19(5 Suppl 6):11-6, (1987); Naito *et al.*, "Reversal of multidrug resistance by an immunosuppressive agent FK-506," *Cancer Chemother & Pharmacol.* 29:195-200 (1992); Pourtier-Manzanedo *et al.*, "FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro," *Anti-Cancer Drugs* 2:279-83 (1991); Epand & Epand, "The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells," *Anti-Cancer Drug Design* 6:189-93 (1991)), VX-710 (2-peperidinecarboxylic acid, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester [ACS 159997-94-1] [US patent number 5,620,971] Germann *et al.*, "Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistance-associated protein MRP" *Anti-Cancer Drugs* 8, 141-155 (1997) ; Germann *et al.*, "Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro" *Anti-Cancer Drugs* 8, 125-140 (1997)), VX-853 ([US patent number 5,543,423] [ACS # 190454-58-1), AHC-52 (methyl 2-(N-benzyl-N-methylamino)ethyl-2, 6-dimethyl-4-(2-isopropylpyrazolo[1,5-a]pyridine-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; [Japanese Patent 63-135381; European Patent 0270926] [ACS 119666-09-0]

Shinoda *et al.*, "In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52," *Cancer Res* 49:1722-6 (1989)), GF-120918 (9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl) ethyl]phenyl]-4 acridinecarboxamide,[US patent 5,604,237] [ACS # 143664-11-3] Hyafil *et al.*, "In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative," *Cancer Res* 53:4595-4602 (1993)), and XR-9051 (3-[(3Z, 6Z)-6-Benzylidene-1-methyl-2,5-dioxopiperazin-3-ylidenemethyl]-N-[4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl]benzamide hydrochloride, [ACS#57-22-7]).

It is also within the scope of this invention to determine the ability of a compound (*e.g.*, an ABCA10 transporter substrate) to interact with ABCA10 transporter without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with ABCA10 transporter without the labeling of either the compound or the ABCA10. McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and ABCA10.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing an ABCA10 transporter target molecule (*e.g.*, an ABCA10 transporter substrate) with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the ABCA10 transporter target molecule. Determining the ability of the test compound to modulate the activity of an ABCA10 transporter target molecule can be accomplished, for example, by determining the ability of the ABCA10 transporter protein to bind to or interact with the ABCA10 transporter target molecule.

Determining the ability of the ABCA10 transporter protein or a biologically active fragment thereof, to bind to or interact with an ABCA10 transporter target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the ABCA10 transporter protein to bind to or interact with an ABCA10 transporter target molecule can be accomplished by

determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.*, intracellular Ca^{2+} , diacylglycerol, IP_3 , and the like), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), cellular transport of, *e.g.*, a reference compound or, *e.g.*, a neurotoxic polypeptide (*e.g.*, β -amyloid) or detecting a target-regulated cellular response.

10 In yet another embodiment, an assay of the present invention is a cell-free assay in which an ABCA10 transporter protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the ABCA10 transporter protein or biologically active portion thereof is determined. Preferred biologically active portions of the ABCA10 transporter proteins to be used in assays of the present invention include fragments which participate in interactions with non-ABCA10 transporter molecules, *e.g.*, fragments with high surface probability scores. Binding of the test compound to the ABCA10 transporter protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the ABCA10 transporter protein or biologically active portion thereof with a known compound which binds ABCA10 transporter to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an ABCA10 transporter protein, wherein determining the ability of the test compound to interact with an ABCA10 transporter protein comprises determining the ability of the test compound to preferentially bind to ABCA10 transporter or biologically active portion thereof as compared to the known compound.

30 In another embodiment, the assay is a cell-free assay in which an ABCA10 transporter protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the ABCA10 transporter protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of an ABCA10 transporter protein can be accomplished, for example, by determining the ability of the ABCA10 transporter protein to bind to an ABCA10 transporter target molecule by one of

the methods described above for determining direct binding. Alternatively, for example, ATP binding can be measured. Determining the ability of the ABCA10 transporter protein to bind to an ABCA10 transporter target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of an ABCA10 transporter protein can be accomplished by determining the ability of the ABCA10 transporter protein to further modulate the activity of a downstream effector of an ABCA10 transporter target molecule. For example, the activity of the effector molecule on an appropriate target can be determined or the binding of the effector to an appropriate target can be determined as previously described.

In yet another embodiment, the cell-free assay involves contacting an ABCA10 transporter protein or biologically active portion thereof with a known compound which binds the ABCA10 transporter protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the ABCA10 transporter protein, wherein determining the ability of the test compound to interact with the ABCA10 transporter protein comprises determining the ability of the ABCA10 transporter protein to preferentially bind to or modulate the activity of an ABCA10 transporter target molecule.

The cell-free assays of the present invention are amenable to use of both soluble and/or membrane-bound forms of isolated proteins (e.g., ABCA10 transporter proteins or biologically active portions thereof). In the case of cell-free assays in which a membrane-bound form of an isolated protein is used it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the isolated protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)_n, 3-[(3-

cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either ABCA10 transporter or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to an ABCA10 transporter protein, or interaction of an ABCA10 transporter protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ABCA10 transporter fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione Sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or ABCA10 transporter protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of ABCA10 transporter binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either an ABCA10 transporter protein or an ABCA10 transporter target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated ABCA10 transporter protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with ABCA10 transporter protein or target molecules but which do not interfere with binding of the ABCA10 transporter protein to its target molecule

can be derivatized to the wells of the plate, and unbound target or ABCA10 transporter protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using
5 antibodies reactive with the ABCA10 transporter protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the ABCA10 transporter protein or target molecule.

In another embodiment, modulators of ABCA10 transporter expression are identified in a method wherein a cell is contacted with a
10 candidate compound and the expression of ABCA10 transporter mRNA or protein in the cell is determined. The level of expression of ABCA10 transporter mRNA or protein in the presence of the candidate compound is compared to the level of expression of ABCA10 transporter mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as
15 a modulator of ABCA10 transporter expression based on this comparison. For example, when expression of ABCA10 transporter mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of ABCA10 transporter mRNA or protein expression. Alternatively, when
20 expression of ABCA10 transporter mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of ABCA10 transporter mRNA or protein expression. The level of ABCA10 transporter mRNA or protein expression in the cells can be determined by methods
25 described herein for detecting ABCA10 transporter mRNA or protein.

In yet another aspect of the invention, the ABCA10 transporter proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993)
30 *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with ABCA10 transporter ("ABCA10-binding proteins" or "ABCA10-bp") and are involved in ABCA10 transporter activity. Such ABCA10-binding proteins are also likely to be involved in the propagation of signals by the ABCA10
35 transporter proteins or ABCA10 transporter targets as, for example, downstream elements of an ABCA10-mediated signaling pathway.

Alternatively, such ABCA10-binding proteins are likely to be ABCA10 transporter inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for an ABCA10 transporter protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an ABCA10-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the ABCA10 transporter protein.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of an ABCA10 transporter protein can be confirmed *in vivo*, e.g., in an animal.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., an ABCA10 transporter modulating agent, an antisense ABCA10 transporter nucleic acid molecule, an ABCA10-specific antibody, or an ABCA10-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

2. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

a. Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the ABCA10 transporter nucleotide sequences, described herein, can be used to map the location of the ABCA10 transporter genes on a chromosome. The mapping of the ABCA10 transporter sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, ABCA10 transporter genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the ABCA10 transporter nucleotide sequences. Computer analysis of the ABCA10 transporter sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the ABCA10 transporter sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set

of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. *et al.* (1983) *Science* 220:919-924).

Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and
5 deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the ABCA10 transporter nucleotide sequences to design oligonucleotide primers,
10 sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map an ABCA10 transporter sequence to its chromosome include *in situ* hybridization (described in Fan, Y. *et al.* (1990) *Proc. Natl. Acad. Sci. USA*, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-
15 selection by hybridization to chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical such as
20 colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a
25 higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, Human Chromosomes: A Manual of BABC transporter Techniques (Pergamon Press,
30 New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are
35 preferred for mapping purposes. Coding sequences are more likely to be

conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data (such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the ABCA10 transporter gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

b. Tissue Typing

The ABCA10 transporter sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the

ABCA10 transporter nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

5 Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The ABCA10
10 transporter nucleotide sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences
15 described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals.

20 If a panel of reagents from ABCA10 transporter nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

25 c. Use of ABCA10 Transporter Sequences in Forensic Biology

 DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying,
30 for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, *e.g.*, hair or skin, or body fluids, *e.g.*, blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the
35 biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, *e.g.*, PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (*i.e.*,
5 another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO: 1 or 3 are particularly appropriate for this use as greater numbers of polymorphisms occur
10 in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the ABCA10 transporter nucleotide sequences or portions thereof, *e.g.*, fragments derived from the noncoding regions of SEQ ID NO: 1 or 3 having a length of at least 20 bases, preferably at least 30 bases.

15 The ABCA10 transporter nucleotide sequences described herein can further be used to provide polynucleotide reagents, *e.g.*, labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, *e.g.*, brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of
20 unknown origin. Panels of such ABCA10 transporter probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, *e.g.*, ABCA10 transporter primers or probes can be used to screen tissue culture for contamination (*i.e.*, screen for the presence of a mixture of different types of cells in a culture).

25 3. Predictive Medicine:

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to
30 diagnostic assays for determining ABCA10 transporter protein and/or nucleic acid expression as well as ABCA10 transporter activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant or unwanted ABCA10
35 transporter expression or activity. The invention also provides for prognostic (or

predictive) assays for determining whether an individual is at risk of developing a disorder associated with ABCA10 transporter protein, nucleic acid expression or activity. For example, mutations in an ABCA10 transporter gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with ABCA10 transporter protein, nucleic acid expression or activity.

Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of ABCA10 transporter in clinical trials.

These and other agents are described in further detail in the following sections.

a. Diagnostic Assays

An exemplary method for detecting the presence or absence of ABCA10 transporter protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting ABCA10 transporter protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes ABCA10 transporter protein such that the presence of ABCA10 transporter protein or nucleic acid is detected in the biological sample. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. A preferred agent for detecting ABCA10 transporter mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to ABCA10 transporter mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length ABCA10 transporter nucleic acid, such as the nucleic acid of SEQ ID NO: 1 or 3, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to ABCA10 transporter mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting ABCA10 transporter protein is an antibody capable of binding to ABCA10 transporter protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody,

is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a
5 primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

The detection method of the invention can be used to detect ABCA10 transporter mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of
10 ABCA10 transporter mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of ABCA10 transporter protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for
15 detection of ABCA10 transporter genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of ABCA10 transporter protein include introducing into a subject a labeled anti-ABCA10 transporter antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging
20 techniques.

In one embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting ABCA10 transporter protein, mRNA, or genomic DNA, such that the presence of ABCA10 transporter
25 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of ABCA10 transporter protein, mRNA or genomic DNA in the control sample with the presence of ABCA10 transporter protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of
30 ABCA10 transporter in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting ABCA10 transporter protein or mRNA in a biological sample; means for determining the amount of ABCA10 transporter in the sample; and means for comparing the amount of ABCA10 transporter in the sample with a standard. The compound or agent can be
35 packaged in a suitable container. The kit can further comprise instructions for using the kit to detect an ABCA10 transporter protein or nucleic acid.

b. Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant or unwanted ABCA10 transporter expression or activity. As used herein, the term "aberrant" includes an ABCA10 transporter expression or activity which deviates from the wild type ABCA10 transporter expression or activity. Aberrant expression or activity includes increased or decreased expression or activity, as well as expression or activity which does not follow the wild type developmental pattern of expression or the subcellular pattern of expression. For example, aberrant ABCA10 transporter expression or activity is intended to include the cases in which a mutation in the ABCA10 transporter gene causes the ABCA10 transporter gene to be under-expressed or over-expressed and situations in which such mutations result in a non-functional ABCA10 transporter protein or a protein which does not function in a wild-type fashion, e.g., a protein which does not interact with an ABCA10 transporter ligand or one which interacts with a non-ABCA10 transporter ligand. As used herein, the term "unwanted" includes an unwanted phenomenon involved in a biological response. For example, the term "unwanted" includes an ABCA10 transporter expression or activity which is undesirable in a subject.

The assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with a misregulation in ABCA10 transporter protein activity or nucleic acid expression. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disorder associated with a misregulation in ABCA10 transporter protein activity or nucleic acid expression. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant or unwanted ABCA10 transporter expression or activity in which a test sample is obtained from a subject and ABCA10 transporter protein or nucleic acid (e.g., mRNA or genomic DNA) is detected, wherein the presence of ABCA10 transporter protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted ABCA10 transporter expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant or unwanted ABCA10 transporter expression or activity, e.g., a cancer where the cells of the cancer have developed multidrug resistance. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant or unwanted ABCA10 transporter expression or activity in which a test sample is obtained and ABCA10 transporter protein or nucleic acid expression or activity is detected (e.g., wherein the abundance of ABCA10 transporter protein or nucleic acid expression or activity is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant or unwanted ABCA10 transporter expression or activity).

The methods of the invention can also be used to detect genetic alterations (also referred to as "allelic variation") in an ABCA10 transporter gene. In one embodiment, the method comprises the following two steps: (1) obtaining from a sample a polynucleotide that hybridizes to the human ABCA10 transporter gene (*i.e.*, SEQ ID NO: 1 or 3), and (2) determining whether the polynucleotide is identical to a portion, or the full length sequence, of SEQ ID NO:1 or 3. In another embodiment, the method is used to determine if a subject with the altered gene is at risk for a disorder characterized by misregulation in ABCA10 transporter protein activity or nucleic acid expression. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding an ABCA10 protein, or the mis-expression of the ABCA10 transporter gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from an ABCA10 transporter gene; 2) an addition of one or more nucleotides to an ABCA10 transporter gene; 3) a substitution of one or more nucleotides of an ABCA10 transporter gene, 4) a chromosomal rearrangement of an ABCA10 transporter gene; 5) an alteration in the level of a messenger RNA transcript of an ABCA10 transporter gene, 6) aberrant modification of an ABCA10 transporter gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of

an ABCA10 transporter gene, 8) a non-wild type level of an ABCA10-protein, 9) allelic loss of an ABCA10 transporter gene, and 10) inappropriate post-translational modification of an ABCA10-protein. As described herein, there are a large number of assays known in the art which can be used for detecting alterations in an ABCA10 transporter gene. A preferred biological sample is a tissue or serum sample isolated by conventional means from a subject.

In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the ABCA10-gene (see Abravaya *et al.* (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a subject, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to an ABCA10 transporter gene under conditions such that hybridization and amplification of the ABCA10-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. *et al.*, (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. *et al.*, (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi, P.M. *et al.* (1988) *Bio-Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in an ABCA10 transporter gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and

fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score
5 for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in ABCA10 transporter can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of
10 oligonucleotides probes (Cronin, M.T. *et al.* (1996) *Human Mutation* 7: 244-255; Kozal, M.J. *et al.* (1996) *Nature Medicine* 2: 753-759). For example, genetic mutations in ABCA10 transporter can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through
15 long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to
20 all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the ABCA10
25 transporter gene and detect mutations by comparing the sequence of the sample ABCA10 transporter with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also
30 contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.* (1996) *Adv. Chromatogr.* 36:127-162; and Griffin *et al.* (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

35 Other methods for detecting mutations in the ABCA10 transporter gene include methods in which protection from cleavage agents is used to

detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes formed by hybridizing (labeled) RNA or DNA containing the wild-type ABCA10 transporter sequence with

5 potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to base pair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to

10 enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See,

15 for example, Cotton *et al.* (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba *et al.* (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-

20 stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in ABCA10 transporter cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-

25 1662). According to an exemplary embodiment, a probe based on an ABCA10 transporter sequence, *e.g.*, a wild-type ABCA10 transporter sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example,

30 U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in ABCA10 transporter genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic

35 acids (Orita *et al.* (1989) *Proc Natl. Acad. Sci USA*: 86:2766, see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet. Anal. Tech. Appl.*

9:73-79). Single-stranded DNA fragments of sample and control ABCA10 transporter nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the
5 detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded
10 heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985)
15 *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA
20 (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and
25 then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl Acad. Sci USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing
30 membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that
35 amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under

appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an ABCA10 transporter gene.

Furthermore, any cell type or tissue in which ABCA10 transporter is expressed may be utilized in the prognostic assays described herein.

c. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs) on the expression or activity of an ABCA10 transporter protein can be applied not only in ABCA10 transporter drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase ABCA10 transporter gene expression, protein levels, or upregulate ABCA10 transporter activity, can be monitored in clinical trials of subjects exhibiting decreased ABCA10 transporter gene expression, protein levels, or downregulated ABCA10 transporter activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease ABCA10 transporter gene expression, protein levels, or downregulate ABCA10 transporter activity, can be monitored in clinical trials of subjects exhibiting increased ABCA10 transporter gene expression, protein levels, or upregulated ABCA10 transporter activity. In such clinical trials, the expression or activity of an ABCA10 transporter gene, and preferably, other genes that have been implicated in, for example, an ABCA10-associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.

For example, and not by way of limitation, genes, including ABCA10, that are modulated in cells by treatment with an agent (e.g.,

compound, drug or small molecule) which modulates ABCA10 transporter activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on ABCA10-associated disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and
5 analyzed for the levels of expression of ABCA10 transporter and other genes implicated in the ABCA10-associated disorder, respectively. The levels of gene expression (*e.g.*, a gene expression pattern) can be quantified by northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by
10 measuring the levels of activity of ABCA10 transporter or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent.

15 In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration
20 sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an ABCA10 transporter protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the ABCA10 transporter protein, mRNA, or genomic DNA in the post-administration
25 samples; (v) comparing the level of expression or activity of the ABCA10 transporter protein, mRNA, or genomic DNA in the pre-administration sample with the ABCA10 transporter protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the
30 agent may be desirable to increase the expression or activity of ABCA10 transporter to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of ABCA10 transporter to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent. According
35 to such an embodiment, ABCA10 transporter expression or activity may be

used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.

4. Methods of Treatment:

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant or unwanted ABCA10 transporter expression or activity. With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.

"Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the ABCA10 transporter molecules of the present invention or ABCA10 transporter modulators according to that individual's drug response genotype.

Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

a. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted ABCA10 transporter expression or activity, by administering to the subject an ABCA10 transporter or an agent which modulates ABCA10 transporter expression or at least one ABCA10 transporter activity. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted ABCA10 transporter expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.

Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the ABCA10 transporter aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression.

Depending on the type of ABCA10 transporter aberrancy, for example, an ABCA10, ABCA10 transporter agonist or ABCA10 transporter antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

5 b. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating ABCA10 transporter expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with an ABCA10 transporter or agent that
10 modulates one or more of the activities of ABCA10 transporter protein activity associated with the cell. An agent that modulates ABCA10 transporter protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of an ABCA10 transporter protein (e.g., an ABCA10 transporter substrate), an ABCA10 transporter antibody, an
15 ABCA10 transporter agonist or antagonist, a peptidomimetic of an ABCA10 transporter agonist or antagonist, or other small molecule. In one embodiment, the agent stimulates one or more ABCA10 transporter activities. Examples of such stimulatory agents include active ABCA10 transporter protein and a nucleic acid molecule encoding an ABCA10 transporter that has been
20 introduced into the cell. In another embodiment, the agent inhibits one or more ABCA10 transporter activities. Examples of such inhibitory agents include antisense ABCA10 transporter nucleic acid molecules, anti-ABCA10 transporter antibodies, and ABCA10 transporter inhibitors. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively,
25 *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of an ABCA10 transporter protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a
30 screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) ABCA10 transporter expression or activity. In another embodiment, the method involves administering an ABCA10 transporter protein or nucleic acid molecule as therapy to compensate for reduced, aberrant, or unwanted ABCA10 transporter expression or activity.

Stimulation of ABCA10 transporter activity is desirable in situations in which ABCA10 transporter is abnormally downregulated and/or in which increased ABCA10 transporter activity is likely to have a beneficial effect. For example, stimulation of ABCA10 transporter activity is desirable in situations in which an ABCA10 transporter is downregulated and/or in which increased ABCA10 transporter activity is likely to have a beneficial effect. Likewise, inhibition of ABCA10 transporter activity is desirable in situations in which ABCA10 transporter is abnormally upregulated and/or in which decreased ABCA10 transporter activity is likely to have a beneficial effect.

10 In one embodiment, an agent found to inhibit ABCA10 transporter activity is used in combination with another therapy such that the targeting of that therapy across the blood-brain-barrier is achieved.

c. Pharmacogenomics

The ABCA10 transporter molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on ABCA10 transporter activity (e.g., ABCA10 transporter gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) ABCA10-associated disorders associated with aberrant or unwanted ABCA10 transporter activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer an ABCA10 transporter molecule or ABCA10 transporter modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with an ABCA10 transporter molecule or ABCA10 transporter modulator.

30 Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. *et al.* (1996) *Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 and Linder, M.W. *et al.* (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions

transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (*e.g.*, a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants.) Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the "candidate gene approach", can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug's target is known (*e.g.*, an ABCA10 transporter protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Alternatively, a method termed the "gene expression profiling", can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., an ABCA10 transporter molecule or ABCA10 transporter modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an ABCA10 transporter molecule or ABCA10 transporter modulator, such as a modulator identified by one of the exemplary screening assays described herein.

EXAMPLE

In this example, two polynucleotide sequences encoding ABCA10 are described. The first sequence, the polynucleotide sequence for which is shown in Figure 1 (SEQ ID NO:1), is 5581 nucleotides in length. The encoded amino acid sequence is shown in Figure 2, as SEQ ID NO:2.

A second polynucleotide sequence is shown in SEQ ID NO:3, and differs from SEQ ID NO:1 in that it has a 42 base pair insert, resulting in a 14 amino acid insert in the encoded protein.

The 42 base pair insert in SEQ ID NO:3 is located at positions 1259-1301. SEQ ID NO:1 and 3 align exactly when the 42 base pair insert is taken into account.

Figure 3 shows the start codon for both sequences, at nucleotides 254-257.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

What is claimed is:

1. An isolated nucleic acid molecule encoding an ABCA10 transporter or a functional fragment thereof, wherein said nucleic acid molecule is selected from the group consisting of:
 - (a) a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a portion of, or the full length of, the nucleotide sequence of SEQ ID NO: 1 or 3;
 - (b) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 90% similar to a portion of, or the full length of, the amino acid sequence of SEQ ID NO: 2 or 4; and
 - (c) a nucleic acid molecule comprising a nucleotide sequence which hybridizes to the nucleotide sequence of SEQ ID NO: 1 or 3 under stringent conditions.
2. The isolated nucleic acid molecule of claim 1 comprising the nucleotide sequence set forth in SEQ ID NO: 1 or 3.
3. The isolated nucleic acid molecule of claim 1 which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 or 4.
4. The isolated nucleic acid molecule of claim 1 which encodes a polypeptide comprising a naturally occurring allelic variant of the amino acid sequence set forth in SEQ ID NO: 2 or 4, wherein said allelic variant binds to an antibody that selectively binds to the polypeptide of SEQ ID NO: 2 or 4.
5. An oligonucleotide primer comprising at least 12 contiguous nucleotides of SEQ ID NO: 1 or 3, or a complement thereof from a region specific to ABCA10 transporters.
6. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid molecule of claim 1.

7. An isolated nucleic acid molecule comprising the nucleic acid molecule of claim 1 and a nucleotide sequence encoding a heterologous polypeptide.
8. A vector comprising the nucleic acid molecule of claim 1.
9. The vector of claim 8, which is an expression vector.
10. A host cell transfected with the expression vector of claim 9.
11. A method of producing a polypeptide comprising culturing the host cell of claim 10 in an appropriate culture medium to, thereby, produce the polypeptide.
12. An isolated polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4 or a functional fragment thereof;
 - (b) a polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4, wherein said allelic variant binds to an antibody that selectively binds to the polypeptide of SEQ ID NO: 2 or 4;
 - (c) a polypeptide comprising a functional fragment of the allelic variant of (b);
 - (d) a polypeptide comprising an amino acid sequence which is at least 90% similar to the amino acid sequence of SEQ ID NO: 2 or 4, wherein said amino acid sequence is an ABCA10 transporter; and
 - (e) a polypeptide comprising a functional fragment of the amino acid sequence of (d).
13. The polypeptide of claim 12, further comprising at least one heterologous amino acid sequence at the amino- or the carboxyl- terminus of said polypeptide.
14. An antibody which selectively binds to a polypeptide of claim 12.

15. A method for detecting the presence of a polypeptide of claim 12 in a biological sample comprising:

- (a) contacting the sample with a compound which selectively binds to the polypeptide; and
- (b) detecting the presence of a complex between said compound and said polypeptide.

16. The method of claim 15, wherein the compound which binds to the polypeptide is an antibody.

17. A kit comprising a compound which selectively binds to a polypeptide of claim 12 and instructions for use.

18. A method for detecting the presence of a nucleic acid molecule of claim 1 in a biological sample comprising:

- (a) contacting said sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
- (b) detecting the presence of a complex of said nucleic acid molecule and said probe or primer.

19. The method of claim 18, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

20. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

21. A method for identifying a compound which binds to a polypeptide of claim 12 comprising:

- (a) contacting said polypeptide, or a cell expressing said polypeptide with a test compound; and
- (b) determining whether the polypeptide binds to the test compound.

22. The method of claim 21, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- (a) direct detection of binding;
- (b) detection of binding using a competitive binding assay; and
- (c) detection of binding using an assay for ABCA10 transporter

activity.

23. A method for modulating the activity of a polypeptide of claim 12 comprising contacting said polypeptide or a cell expressing said polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

24. A method for identifying a compound which modulates the activity of a polypeptide of claim 12 comprising:

- (a) contacting a polypeptide of claim 12 with a test compound; and
- (b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

25. A method for detecting an allelic variation of the nucleic acid of SEQ ID NO: 1 or 3 or an orthologue thereof in a biological sample, comprising:

- (a) obtaining from said sample a polynucleotide that hybridizes to the nucleic acid of SEQ ID NO: 1 or 3 or the orthologue thereof; and
- (b) determining whether said polynucleotide is identical to a portion, or the full length, of SEQ ID NO: 1 or 3 or the orthologue thereof.

26. A composition comprising a pharmaceutically effective amount of the nucleic acid molecule of SEQ ID NO: 1 or 3 or a functional fragment thereof and a pharmaceutically acceptable carrier.

27. A composition comprising a pharmaceutically effective amount of an antisense oligonucleotide capable of specifically hybridizing to a portion, or the full length, of SEQ ID NO: 1 or 3 and a pharmaceutical acceptable carrier.

28. A transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous ABCA10 gene, wherein said homozygous disruption prevents the expression of functional ABCA10 protein, and wherein said homozygous disruption results in said transgenic mouse being sterile.

1/13

ABCA10 nucleotide sequence

Sequence range: 1 to 5680

GAGATAAGCGTGCCTCAACAAATTCAGGCTCTTCTGTACAAGAATTTTCTTAAAAATGGAGAATAAAAAGAGAGTTT
ATTGGAATGGACAATAACATTGTTTCTAGGGCTATATTTGTGCATCTTTTCGGAACACTTCAGAGCTACCGTTTTCC
TGAACAACCTCCTAAAGTCTGGGAAGCGTGGATCAGTTTAATGACTCTGGCCTGGTAGTGGCATATACACCAGTCAG
TAACATAACACAAAGGATAATGAATAAGATGGCCTTGGCTTCTTTATGAAAGGAAGAACAGTCATTGGGACACCAGA
TGAAGAGACCATGGATATAGAACTTCAAAAAAATACCATGAAATGGTGGGAGTTATATTTAGTGATACTTTCTCATA
TCGCCTGAAGTTTAATTTGGGGATATAGAATCCCAGTTATAAAGGAGCACTCTGAATACACAGAACACTGTTGGGCCAT
GCATGGTGAAATTTTTTGTACTTGGCAAAGTACTGGCTAAAAGGGTTGTAGCTTTTCAAGCTGCAATTAATGCTGC
AATTATAGAAGTCACAACAAATCATTCTGTAATGGAGGAGTTGACGTGAGTTATTGGAATAAATATGAAGATACCACC
TTTCATTTCTAAGGGAGAAATATGAATGAATGGTTTCATTTTACTTGTAGTTTCTTTCTTTCTTTTATATACTT
TGCATCATTAATGTTTGAAGGGAAAGAGGAAAATTTAAGAACTGATGACAGTAATGGGTCTCCGAGAGTCAGCATT
CTGGCTCTCCTGGGGATTGACATACATTTGCTTCATCTTCATTATGTCCATTTTATGGCTCTGGTCATAACATCAAT
CTCAATTGTATTTCACTGGCTTCATGGTGATATTCACACTCTATAGCTTATATGGCCTTTCTTTGATAGCATTGGC
TTTCCTCATGAGTGTTTTAATAAGGAAACCTATGCTCGCTGGTTTGGCTGGATTTCTTTCACTGTATTTTGGGGATG
TCTGGGATTCAGTGTTATACAGACAACCTCCTTTATCTTTGGGATGGGTATTAAGTCTTCTAGCCCTTTTGCCTT
CACTGCTGGAATGGCCAGATTACACACCTGGATAATTAAGTGGTGTTATTTTTCTGATCCCTCTGGGGATTC
ATACAAAATGATAGCCACTTTTTTCATTTTGGCATTGATACTCTTTTCTATTTGATATTCACATTATATTTTGAAGC
AGTTTTACCTTCCTCATTTTGGTCCAAACATCAAAATACTCATGAAATCTTTGAGAATGAAATAAATCCTGAGCA
TTCCTCTGATGATTCTTTTGAACCGGTGTCTCCAGAATTCATGGAAAAGAAGCCATAAGAATCAGAAATGTTATAAA
AGAATATAATGAAAGACTGGAAAAGTAGAAGCATTGCAAGGCATATTTTTTGACATATATGAAGACAGATCACTGC
AATACTTGGGCATAATGGAGCTGGTAAATCAACACTGCTAAACATTCTTAGTGGATTGTCTGTTTCTACAGAAGGATC
AGCCACTATTTATAATACTCAACTCTCTGAAATAACTGACATGGAAGAAATTAGAAAGAATATTGGATTTTGTCCACA
GTTCAATTTTCAATTTGACTTCTCACTGTGAGAGAAAACCTCAGGGTATTTGCTAAAATAAAAGGGATTAGCCAAA
GGAAGTGAACAAGAGGTAAAAAGAATTATAATGGAATTAGACATGCAAGCATTCAAGACATTATTGCTAAAAAATT
AAGTGGTGGGCAGAAGAGAAAACCTAAGCTAGGGATTGCCATCTTAGGAGATCCTCAGGTTTTGCTGCTAGATGAACC
AACTGCTGGATTGGATCCCTTTTCAAGACCCGAGTGTGGAGCCTCCTGAAGGAGCATAAAGTAGACCGACTTATCCT
CTTCAGTACCCAATTCATGGATGAGGCTGACATCTTGGCTGATAGGAAAGTATTTCTGTCTAATGGGAAGTTGAAATG
TGCAGGATCATCTTTGTTTCTGAAGCGAAAGTGGGGTATTGGATATCATTTAAGTTTACACAGGAATGAAATGTGTGA
CACAGAAAAATCACATCCCTTATTAAGCAGCACATTCCTGATGCCAAGTTAACAACAGAAAGTGAAGAAAACTTGT
ATATAGTTTGCCTTTGGAAAAACGAACAAATTTCCAGATCTTTACAGTGACCTTGATAAGTGTTCTGACCAGGGCAT
AAGGAATTATGCTGTTTCACTGACATCTCTGAATGAAGTATTCTTGAACCTAGAAGGAAAATCAGCAATTGATGAACC
AGATTTTGACATTGGGAACAAGAGAAAATACATGTGACAAGAAATACTGGAGATGAGTCTGAAATGGAACAGGTTCT
TTGTTCTCTTCTGAAACAAGAAAGGCTGTCAGTAGTGACGCTCTCTGGAGACGACAAATCTATGCAGTGGCAACACT
TCGCTTCTTAAAGTTAAGGCGTGAAGGAGAGCTTTTGTGTTTGTACTAGTACTTGGAAATGCTTTTATCCCCAT
CATTCTAGAGAAGATAATGTATAAGTAACCTCGTGAACCTCATTGTTGGGAGTTTTCACCCAGTATGATTTCTTTT
TCTGGAACAAATCCGAAGACGCTCTTACCAGCCTGTTAATCGTTAATAATACAGGATCAAATATTGAAGACCTCGT
GCATTCAGTGAAGTGCAGGATATAGTTTTGGAATAGATGACTTTAGAAACAGAAATGGCTCAGATGATCCCTCTA
CAATGGAGCCATCATAGTGTCTGGTGACCAGAAGGATTACAGATTTTCTGTTGCGTGTAATACCAAGAAATTGAATTG
TTTTCTGTTCTTATGGGAATTGTTAGCAATGCCCTATGGGAATTTTAACTTCACGGAGCTTATTCAAACGGAGAG

Fig. 1A

2/13

CACTTCATTTTCTCGTGATGACATAGTGCTGGATCTTGGTTTTATAGATGGGTCCATATTTTGTGTTGATCACAAA
CTGCGTTTCTCCTTTTATCGGCATGAGCAGCATCAGCGATTATAAAAAAATGTTCAATCCCAGTTATGGATTTCAGG
CCTCTGGCCTTCAGCATACTGGTGTGGACAGGCTCTGGTGGACATTCATTATACTTCTTGATTCTCTTTTCAATACA
TTTAATTTACTACTTCATATTTCTGGGATTCAGCTTTCATGGGAACTCATGTTTGTGTTTGGTGGTATGCATAATTGG
TTGTGCAGTTTCTTTATATTCCTCACATATGTGCTTTCATTTCATCTTCGCAAGTGGAGAAAAATAATGGCTTTTG
GTCTTTTGGCTTTTTTATTATCTTAATATGTGTATCCACAATTATGGTATCAACTCAATATGAAAACTCAACTTAAT
TTTGTGCATGATTTTCATACCTTCCTTCACCTTGTCTGGGGTATGTCATGTTATTGATCCAGCTCGACTTTATGAGAAA
CTTGGACAGTCTGGACAATAGAATAAATGAAGTCAATAAAACCATTCTTTTAACAACCTTAATACCATACCTTCAGAG
TGTTATTTTCTTTTTGTGATAAGGTGTCTGGAATGAAGTATGGAATGAAATAATGAATAAAGACCCAGTTTTTCAG
AATCTCTCCACGGAGTAGAGAACTCATCCCAATCCGGAAGAGCCCGAAGAAGAAGATGAAGATGTTCAAGCTGAAAG
AGTCCAAGCAGCAATGCACTCACTGCTCCAACTTGGAGGAGGAACCAGTCATAACTGCAAGCTGTTTACACAAGGA
ATATTATGAGACAAAGAAAAGTTGCTTTTCAACAAGAAAGAAGAAAATAGCCATCAGAAATGTTTCTTTTGTGTTAA
AAAAGGTGAAGTTTGGGATTACTAGGACACAATGGAGCTGGTAAAAGTACTTCCATTAATGATAACTGGGTGCAC
AAAGCCAACGTCAGGAGTGGTGGTGTACAAGGCAGCAGCATCAGTAAGGCAACAGCATGACAACAGCCTCAAGTT
CTTGGGGTACTGCCCTCAGGAGAACTCACTGTGGCCCAAGCTTACAATGAAAGAGCACTTGGAGTTGTATGCAGCTGT
GAAAGGACTGGGCAAGAAGATGTGCTCTCAGTATTTACGATTGGTGGAAAGCTCTTAAGCTCCAGGAACAACTTAA
GGCTCTGTGAAAACCTCATCAGAGGGAATAAGAGAAAGCTGTGCTTTGTGTTGAGCATCCTGGGGAACCCATCAGT
GGTGTCTTAGATGAGCCGTTACCGGGATGGACCCGAGGGGCAGCAGCAATGTGGCAGATACTTCAGGCTACCGT
TAAAAACAAGGAGAGGGGCACCTCTTGACCACCCATTACATGTGAGGGCTGAGGCTGTGTGTGACCGTATGGCCAT
GATGGTGTGAGGAACGCTAAGGTGTATTGGTTCCATTCAACATCTGAAAAACAAGTTTGGTAGAGATTATTTACTAGA
AATAAAATGAAAGAACCTACCCAGGTGGAAGCTCTCCACACAGAGATTTTGAAGCTTTTCCACAGGCTGCTTGGCA
GGAAAGATATCTCTTTAATGGCGTATAAGTTACCTGTGGAGGATGTCCACCCTCTATCTCGGGCTTTTTCAAGTT
AGAGGCGATGAAACAGACCTTCAACCTGGAGGAATACAGCCTCTCTCAGGCTACCTTGGAGCAGGTATTCTTAGAACT
CTGTAAAGAGCAGGAGCTGGGAAATGTTGATGATAAAATTGATACAACAGTTGAATGGAAACTTCTCCACAGGAAGA
CCCTTAAATGAAGAACCTCCTAACATTCAATTTTAGGTCTACTACATTGTTAGTTTCCATAATTCTACAAGAATGT
TTCCTTTTACTTAAGTTAACAAAAGAAAACATTTAATAAACATTCAATAATGATTACAGTTTTCATTTTTAAAAATTT
AGGATGAAGGAAACAAGGAAATATAGGGAAAAGTAGTAGACAAAATTAACAAAATCAGACATGTTATTTCATCCCCAAC
ATGGGTCTATTTTGTGCTTAAAAATAATTTAAAAATCATACAATATTAGGTTGGTTTTCGGTTATTATCAATAAAGCT
AACACTGAGAACATTTTACAATAAAAAATATGAGTTTTTACCTGAACCTTCAATGTATCAGCTATTTTAAACATT
ATTTACTCGGATTCTAATTTAATGTGACATTGACTATAAGAAGGTCTGATAAACTGATGAAATGGCACAGCATAACAT
TTAATTATAATGACATTCTGATTATAAAATAAATGCATGTGAATTTTAGTACATATTGAAGTTATATGGAAGAAGATA
GCCATAATCTGTAAGAAAGTACCGCAGTTAATATTTTCTTTAGCCAACCTATATTCAATGTATTTTATGGATCCTT
TTTCAAAGGTAGTATCAGTAGGCATAGTCATTTTCTGTATCTTTACCTCACAGTTCATGAACATTTCCCATGTGAT
TATAGCACTTTTGTGTTATATAATTGCTGCATTAATGTTATAGCTGTATTGATGTAATACCAGAGTTGTACGTTTGG
GTTATATGCAAGTTATTTCTTAGAAATAAAACTTTGATGGACTTTTAAAAAAAAAAAAAAAAAAAA

Fig. 1B

3/13

ABCA10 peptide sequence

Sequence range: 1 to 1529

MNKMALASFMKGRTVIGTPDEETMDIELPKKYHEMVGVI FSDTFSYRLKFNWGYRIPVKEHSEYTEHCWAMHGEIFCYLAKYWLKGFV
AFQAAINA AIEVTTNHSVMEELTSVIGINMKIPPFISKGEIMNEWFHFTCLVSFSSFIYFASLNVARERGGFKKLMVMGLRESAFWL
SWGLTYICFIFIMSIFMALVITSISIVFHTGFMVIFTLSYLYGLSLIALAFMSVLIRKPMLAGLAGFLFTVFWGCLGFTVLYRQLPLS
LGWVLSLLSPFAFTAGMAQITHLDNYLSGVIFPDPSGDSYKMIATFFILAFDTLFYLI FTLYFERVL PSSFWSKHQNTHEIFENEINP
EHSSDDSFEPVSPEFHGKEAIRIRNVIKEYNGKTGKVEALQGIFFDIYEGQITAILGHNGAGKSTLLNILSGLSVSTEGSATIYNTQLS
EITDMEIEIRKNIGFCPQNFQDFLTVRENLRVFAKIKGIQPKVEQEVEVKRIIMELDMQSIQDI IAKKLSGGQKRKLTGLIAILGDPQV
LLLEPTAGLDPF SRHRVWSLLKEHKVDRLILFSTQFMDEADILADRKVFLSNGKLKAGSSLFLKRKWGIGYHLSLHRNEMCDTEKIT
SLIKQHIPDAKL TTESEEKLVYSLPLEKTNKFPDLYSDLKCSDDQIRNYAVSVTSLNEVFLNLEGKSAIDEPDFDIGKQEKIHVTRNT
GDESEMEQVLC SLPETRAVSSAALWRRQIYAVATLRFLKLRERRALLC LLLVLGIAFIPIILEKIMYKVTRETHCWEFSPSMYFLSL
EQIPKTPLTSL L I VNNTGSNIEDLVHSLKCQDIVLEIDDFRNRNGSDDPSYNGAII VSGDQKDYRFSVACNTKKLNCFPVLMGIVSNAL
MGIFNFTELIQTESTSFRDDIVLDLGFIDGSI FLLLITNCVSPFIGMSSISDYKKNVQSQLWISGLWPSAYWCGQALVDIPLYFLILF
SIHLIYYFIFLGFQLSWELMFVLVVCII GCAVSLIFLTYVLSFIFRKWRKNNGFWSFGFFIILICVSTIMVSTQYEKLNILCMIFIPS
FTLLGYVMLLIQLDFMRNLDLNRINEVNKTILLTTLIPYLSVIFLVIRCLEMKYGNEMNKDPVFRISPRSRETHPNPEEPEEED
EDVQAERVQAANALTAPNLEEEPVITASCLHKEYYETKKSCFSTRKKKIAIRNVSFVKKGEVLGLLGHNGAGKSTS IKMITGCTKPTA
GVVVLQGSRASVRQQHDNSLKFLGYCPQENSLWPKL TMKEHELYAAVKGLGKEDAALSISRLVEALKLQEQLKAPVKTLSEGIKRKLC
FVLSILGNPSVLLDEPFTGMDPEGQQMWQILQATVKNKERGTLLTTHYMSEAEAVCDRMAMMVSGLRCIGSIQHLKNKFGRDYLLE
IKMKEPTQVEALHTEILKLFQAAWQERYSSL MAYKL PVEDVHPLSRAFFKLEAMKQTFNLEEYSLSQATLEQVFLELCKEQELGNVDD
KIDTTVEWKLLPQEDP

Fig. 2

Summary View of ABCA10 translation

>ABCA10.cDNA Protein	#1	GAGATAAGCG TGGTCAACA AATTCAGGCT CTTCGTACA AGAATTTCT TAAAAATGG AGAATAAAAA R . A C V N K F R L F C T R I F L K N G E . K
>ABCA10.cDNA Protein	#71	GAGAGTTTAT TGGATGGAC AATAACATTG TTTCTAGGCG TATATTGTG CATCTTTTCG GAACACTTCA E S L L E W T I T L F L G L Y L C I F S E H F R
>ABCA10.cDNA Protein	#141	GAGCTACCGG TTTTCCTGAA CAACCTCCTA AAGTCCTGGG AAGCGTGGAT CAGTTTAATG ACTCTGGCCT A T R F P E Q P P K V L G S V D Q F N D S G L
>ABCA10.cDNA Protein	#211	GGTAGTGGCA TATACACCAG TCAGTAACAT AACACAAAGG ATAATGAATA AGATGGCCTT GGCTTCCTTT V V A Y T P V S N I T Q R I M N K M A L A S F
>ABCA10.cDNA Protein	#281	ATGAAAGGAA GAACAGTCAT TGGGACACCA GATGAAGAGA CCATGGGATAT AGAACTTCCA AAAAAATACC M K G R T V I G T P D E E T M D I E L P K K Y H
>ABCA10.cDNA Protein	#351	ATGAAATGGT GGGAGTTATA TTTAGTGATA CTTTCTCATA TGGCCTGAAG TTTAATTGGG GATATAGAAT E M V G V I F S D T F S Y R L K F N W G Y R I
>ABCA10.cDNA Protein	#421	CCCAGTTATA AAGGAGCACT CTGAATACAC AGAACACTGT TGGGCCCATGC ATGGTGAAT TTTTGTAC P V I K E H S E Y T E H C W A M H G E I F C Y
>ABCA10.cDNA Protein	#491	TTGGCAAAGT ACTGGCTAAA AGGGTTTGTA GCITTTCAAG CTGCAATTAA TGCTGCAATT ATAGAAGTCA L A K Y W L K G F V A F Q A A I N A A I I E V T

Fig. 3A

>ABCA10.cDNA Protein	#561	CAACAAATCA TTCTGTAATG GAGGAGTTGA CGTCAGTTAT TGAATAAAT ATGAAGATAC CACCTTTTCAT T N H S V M E E L T S V I G I N M K I P P F I
>ABCA10.cDNA Protein	#631	TTCTAAGGGA GAAATTATGA ATGAATGGTT TCAITTTTACT TGCTTAGITT CTTCTCTTC TTTTATATAC S K G E I M N E W F H F T C L V S F S S F I Y
>ABCA10.cDNA Protein	#701	TTTGCAATCAT TAAATGTTGC AAGGGAAGA GGAATAATTA AGAACTGAT GACAGTAATG GGTCTCCGAG F A S L N V A R E R G K F K K L M T V M G L R E
>ABCA10.cDNA Protein	#771	AGTCAGCAIT CTGGCTCTCC TGGGGATTGA CATACATTG CTCATCTTC ATTATGCCA TTTTATGGC S A F W L S W G L T Y I C F I F I M S I F M A
>ABCA10.cDNA Protein	#841	TCGGTCATA ACATCAATCT CAATTGTATT TCATACTGGC TTCATGGTGA TATTCACACT CTATAGCTTA L V I T S I S I V F H T G F M V I F T L Y S L
>ABCA10.cDNA Protein	#911	TATGGCCTTT CTTTGATAGC ATTGGCTTTC CTCATGAGTG TTTTAATAAG GAAACCTATG CTCGCTGGTT Y G L S L I A L A F L M S V L I R K P M L A G L
>ABCA10.cDNA Protein	#981	TGGCTGGATT TCTCTTCACT GTATTTTGGG GATGCTGGG ATTCACGTG TTATACAGAC AACTTCCTTT A G F L F T V F W G C L G F T V L Y R Q L P L
>ABCA10.cDNA Protein	#1051	ATCTTTGGGA TGGGTATTAA GTCTTCTTAG CCCTTTTGCC TTCACTGCTG GAATGGCCCA GATTACACAC S L G W V L S L L S P F A F T A G M A Q I T H
>ABCA10.cDNA Protein	#1121	CTGGATAATT ACTTAAGTGG TGTATTATTT CCTGATCCCT CTGGGGATTC ATACAAAATG ATAGCCACTT L D N Y L S G V I F P D P S G D S Y K M I A T F

Fig. 3B

>ABCA10. cDNA Protein	#1191	TTTTCATTTT GGCATTGTAT ACTCTTTTCT ATTGTATATT CACATTATAT TTTGAGCGAG TTTTACCTTC F I L A F D T L F Y L I F T L Y F E R V L P S
>ABCA10. cDNA Protein	#1261	CTCATTTTGG TCCAAACATC AAAATACTCA TCATGAAATC TTTGAGAATG AAATAAATCC TGAGCATTCCTC S F W S K H Q N T H H E I F E N E I N P E H S
>ABCA10. cDNA Protein	#1331	TCTGATGATT CTTTGAACCC GGTGTCCTCCA GAATTCATG GAAAAGAAGC CATAAGAATC AGAAATGTTA S D S F E P V S P E F H G K E A I R I R N V I
>ABCA10. cDNA Protein	#1401	TAAAGAATA TAATGGAAAG ACTGGAAAAG TAGAAGCATT GCAAGGCATA TTTTITGACA TATATGAAGG K E Y N G K T G K V E A L Q G I F F D I Y E G
>ABCA10. cDNA Protein	#1471	ACAGATCACT GCAATACTTG GGCATAATGG AGCTGGTAA TCAACACTGC TAAACATTCT TAGTGGATTG Q I T A I L G H N G A G K S T L L N I L S G L
>ABCA10. cDNA Protein	#1541	TCTGTTTCTA CAGAAGATC AGCCACTATT TATAATACTC AACTCTCTGA AATAACTGAC ATGGAAGAAA S V S T E G S A T I Y N T Q L S E I T D M E E I
>ABCA10. cDNA Protein	#1611	TTAGAAAGAA TATTGGATT TGTCCACAGT TCAATTTTCA ATTGACTTC CTCACTGTGA GAGAAAACCT R K N I G F C P Q F N F Q F D F L T V R E N L
>ABCA10. cDNA Protein	#1681	CAGGGTATTT GCTAAATAA AAGGGATTCA GCCAAGGAA GTGGACAAG AGGTAAAAAG AATTATAATG R V F A K I K G I Q P K E V E Q E V K R I I M
>ABCA10. cDNA Protein	#1751	GAATTAGACA TGCAAGCAT TCAAGACATT ATTGCTAAAA AATTAAAGTG TGGGCAGAAG AGAAAACTAA E L D M Q S I Q D I I A K K L S G G Q K R K L T

Fig. 3C

>ABCA10. cDNA Protein	#1821	CACTAGGGAT TGCCATCTTA GGAGATCCTC AGGTTTIGCT GCTAGATGAA CCAACTGCTG GATTGGATCC L G I A I L G D P Q V L L L D E P T A G L D P
>ABCA10. cDNA Protein	#1891	CTTTCAAGA CACCGAGTGT GGAGCCTCCT GAAGGAGCAT AAAGTAGACC GACTTATCCT CTTCAGTACC F S R H R V W S L L K E H K V D R L I L F S T
>ABCA10. cDNA Protein	#1961	CAATTCATGG ATGAGGCTGA CATCTTGGCT GATAGGAAAG TATTTCTGTC TAATGGGAAG TTGAATGTG Q F M D E A D I L A D R K V F L S N G K L K C A
>ABCA10. cDNA Protein	#2031	CAGGATCATC TTTGTTTCTG AAGCGAAAGT GGGGTATTGG ATATCATTTA AGTTTACACA GGAATGAAAT G S S L F L K R K W G I G Y H L S L H R N E M
>ABCA10. cDNA Protein	#2101	GTGTGACACA GAAAAATCA CATCCCTTAT TAAGCAGCAC ATTCTGTGAT CCAAGTTAAC AACAGAAAGT C D T E K I T S L I K Q H I P D A K L T T E S
>ABCA10. cDNA Protein	#2171	GAAGAAAAAC TTGTATATAG TTGCGCTTGG GAAAAACGA ACAAAATTC AGATCTTTAC AGTGACCTTG E E K L V Y S L P L E K T N K F P D L Y S D L D
>ABCA10. cDNA Protein	#2241	ATAAGTGTTC TGACCAGGGC ATAAGGAATT ATGCTGTTTC AGTGACATCT CTGAATGAAG TATCTTGAA K C S D Q G I R N Y A V S V T S L N E V F L N
>ABCA10. cDNA Protein	#2311	CCTAGAAGGA AAATCAGCAA TTGATGAACC AGATTTTGAC ATTGGGAAAC AAGAGAAAAT ACATGTGACA L E G K S A I D E P D F D I G K Q E K I H V T
>ABCA10. cDNA Protein	#2381	AGAAATACTG GAGATGAGTC TGAATGGAA CAGGTTCCTT GTTCTCTTCC TGAACAAGA AAGGCTGTCA R N T G D E S E M E Q V L C S L P E T R K A V S

Fig. 3D

>ABCA10.cDNA Protein	#2451	GTAGTGCAGC TCTCTGGAGA CGACAAATCT ATGCAGTGGC AACACTTCGC TTCTTAAAGT TAAGGCGTGA S A A L W R R Q I Y A V A T L R F L K L R R E
>ABCA10.cDNA Protein	#2521	AAGGAGAGCT CTTTGTGTT TGTTACTAGT ACTTGGAAAT GCITTTATCC CCATCATTTCT AGAGAAGATA R R A L L C L L L V L G I A F I P I I L E K I
>ABCA10.cDNA Protein	#2591	ATGTATAAG TAACTCGTGA AACTCATTGT TGGGAGTTT CACCAGTAT GTATTCCIT TCTCTGGAAC M Y K V T R E T H C W E F S P S M Y F L S L E Q
>ABCA10.cDNA Protein	#2661	AAATCCCGAA GAGCCCTCTT ACCAGCCTGT TAATCGTTAA TAATACAGGA TCAATATTG AAGACCTCGT I P K T P L T S L L I V N N T G S N I E D L V
>ABCA10.cDNA Protein	#2731	GCATTCAC TG AAGTGCAGG ATATAGTTT GGAAATAGAT GACTTTAGAA ACAGAAATGG CTCAGATGAT H S L K C Q D I V L E I D D F R N R N G S D D
>ABCA10.cDNA Protein	#2801	CCCTCCTACA ATGGAGCCAT CATAGTGCT GGTGACCAGA AGGATTACAG ATTTCTGTT GCGTGTAAATA P S Y N G A I I V S G D Q K D Y R F S V A C N T
>ABCA10.cDNA Protein	#2871	CCAAGAAAT GAATTGTTT CCTGTCTTA TGGGAATTGT TAGCAATGCC CTTATGGGAA TTTTAACTT K K L N C F P V L M G I V S N A L M G I F N F
>ABCA10.cDNA Protein	#2941	CAGGAGCTT ATTCAAACGG AGAGCACTTC ATTTCTCGT GATGACATAG TGCTGGATCT TGGTTTATA T E L I Q T E S T S F S R D D I V L D L G F I
>ABCA10.cDNA Protein	#3011	GATGGTGCCA TATTTTGT GTTGATCACA AACTGCGTT CTCCTTTTAT CGGCATGAGC AGCATCAGCG D G S I F L L L I T N C V S P F I G M S S I S D

Fig. 3E

>ABCA10. cDNA Protein	#3081	ATTATAAAAA AAATGTTCAA TCCCAGTTAT GGATTTCAGG CCTCTGGCCT TCAGCATACT GGTGTGGACA Y K K N V Q S Q L W I S G L W P S A Y W C G Q
>ABCA10. cDNA Protein	#3151	GGCTCTGGTG GACATTCCAT TATACTTCTT GATTCTCTTT TCAATACATT TAATTACTA CTTCATATTT A L V D I P L Y F L I L F S I H L I Y Y F I F
>ABCA10. cDNA Protein	#3221	CTGGGATTCC AGCTTTCATG GGAACTCATG TTGTGTTTGG TGGTATGCAT AATTGGTTGT GCAGTTTCTC L G F Q L S W E L M F V L V V C I I G C A V S L
>ABCA10. cDNA Protein	#3291	TTATATTCTT CACATATGTG CTTCATTTCA TCTTTGGCAA GTGGAGAAAA AATAATGGCT TTGGGCTTTT I F L T Y V L S F I F R K W R K N N G F W S F
>ABCA10. cDNA Protein	#3361	TGGCTTTTTT ATTATCTTAA TATGTGTATC CACAATTATG GTATCAACTC AATATGAAAA ACTCAACTTA G F F I I L I C V S T I M V S T Q Y E K L N L
>ABCA10. cDNA Protein	#3431	ATTTTGTCCA TGATTTTCAT ACCTTCCTTC ACTTTGCTGG GGTATGTGTC GTTATTGATC CAGCTCGACT I L C M I F I P S F T L L G Y V M L L I Q L D F
>ABCA10. cDNA Protein	#3501	TTATGAGAAA CTGGACAGT CTGGACAATA GAATAAATGA AGTCAATAAA ACCATTCTTT TAACAACCTT M R N L D S L D N R I N E V N K T I L L T T L
>ABCA10. cDNA Protein	#3571	AATACCATAC CTTCAGAGTG TTAITTTTCT TTTTGTGATA AGGTGTCTGG AAATGAAGTA TGGAAATGAA I P Y L Q S V I F L F V I R C L E M K Y G N E
>ABCA10. cDNA Protein	#3641	ATAATGAATA AAGACCCAGT TTTTCAGAATC TCTCCACGGA GTAGAGAAAC TCATCCCAAT CCGGAAGAGC I M N K D P V F R I S P R S R E T H P N P E E P

Fig. 3F

>ABCA10.cDNA Protein	#3711	CCGAAGAAGA AGATGAAGAT GTTCAAGCTG AAAGAGTCCA AGCAGCAAAT GCACTCACTG CTCCAAAC TT E E E D E D V Q A E R V Q A A N A L T A P N L
>ABCA10.cDNA Protein	#3781	GGAGGAGGAA CCAGTCATAA CTGCAAGCTG TTTACACAAG GAATATTATG AGACAAAGAA AAGTTGCTTT E E E P V I T A S C L H K E Y Y E T K K S C F
>ABCA10.cDNA Protein	#3851	TCAACAAGAA AGAAGAAAAT AGCCATCAGA AATGTTTCCT TTGTGTAA AAAAGGTGAA GTTTTGGGAT S T R K K I A I R N V S F C V K K G E V L G L
>ABCA10.cDNA Protein	#3921	TACTAGGACA CAATGGAGCT GGTAAAAGTA CTTCATTAA ATGATAACT GGGTGCACAA AGCCAACTGC L G H N G A G K S T S I K M I T G C T K P T A
>ABCA10.cDNA Protein	#3991	AGGAGTGGTG GTGTTACAAG GCAGCAGAGC ATCAGTAAGG CAACAGCATG ACAACAGCCT CAAGTCTTGT G V V V L Q G S R A S V R Q Q H D N S L K F L
>ABCA10.cDNA Protein	#4061	GGGTACTGCC CTCAGGAGAA CTCACTGTGG CCCAAGCTTA CAATGAAGA GCAC TTGGAG TTGTATGCAG G Y C P Q E N S L W P K L T M K E H L E L Y A A
>ABCA10.cDNA Protein	#4131	CTGTGAAAGG ACTGGGCAAA GAAGATGCTG CTCTCAGTAT TTCACGATTG GTGGAAGCTC TTAAGTCCA V K G L G K E D A A L S I S R L V E A L K L Q
>ABCA10.cDNA Protein	#4201	GGAACAAC TT AAGGCTCCTG TGAANA CTCT ATCAGAGGGA ATAAAGAGAA AGCTGTGCTT TGTGTTGAGC E Q L K A P V K T L S E G I K R K L C F V L S
>ABCA10.cDNA Protein	#4271	ATCTGGGGGA ACCCATCAGT GGTGCTTCTA GATGAGCCGT TCACCGGGAT GGACCCCGAG GGGCAGCAGC I L G N P S V V L L D E P F T G M D P E G Q Q Q

Fig. 3G

>ABCA10 .cDNA Protein	#4341	AAATGTGGCA GATACTTCAG GCTACCGTTA AAAACAAGGA GAGGGGCACC CTCTTGACCA CCCATTACAT M W Q I L Q A T V K N K E R G T L L T T H Y M
>ABCA10 .cDNA Protein	#4411	GTCAGAGGCT GAGGCTGTGT GTGACCGTAT GGCCATGATG GTGTCAGGAA CGCTAAGGTG TATTGGTTCC S E A E A V C D R M A M M V S G T L R C I G S
>ABCA10 .cDNA Protein	#4481	ATTCAACATC TGA AAAACAA GTTTGGTAGA GATTATTAC TAGAATAAA AATGAAAGAA CCTACCCAGG I Q H L K N K F G R D Y L L E I K M K E P T Q V
>ABCA10 .cDNA Protein	#4551	TGGAAGCTCT CCACACAGAG ATTTTGAAGC TTTTCCACA GGCTGCTTGG CAGGAAAGAT ATTCTCTTT E A L H T E I L K L F P Q A A W Q E R Y S S L
>ABCA10 .cDNA Protein	#4621	AATGGCGTAT AAGTTACCTG TGGAGGATGT CCACCTCTA TCTCGGGCTT TTTTCAAGTT AGAGGCGATG M A Y K L P V E D V H P L S R A F F K L E A M
>ABCA10 .cDNA Protein	#4691	AAACAGACCT TCAACCTGGA GGAATACAGC CTCTCTCAGG CTACCTTGGG GCAGGTATTC TTAGAACTCT K Q T F N L E E Y S L S Q A T L E Q V F L E L C
>ABCA10 .cDNA Protein	#4761	GTAAGAGACA GGAGCTGGA AATGTTGATG ATAAAATTGA TACAACAGTT GAATGGAAC TTCTCCACA K E Q E L G N V D D K I D T T V E W K L L P Q
>ABCA10 .cDNA Protein	#4831	GGAAGACCTT TAAATGAAG AACCTCCTAA CATTCAATT TAGGTCCTAC TACATTGTTA GTTCCATAA E D P . N E E P P N I Q F . V L L H C . F P .
>ABCA10 .cDNA Protein	#4901	TTCTACAAGA ATGTTTCCTT TTACTTAAGT TAACAAAAGA AAACATTTAA TAAACATTCA ATAATGATTA F Y K N V S F Y L S . Q K K T F N K H S I M I T

Fig. 3H

>ABCA10.cDNA Protein	#4971	CAGTTTTCAT TTTTAAAAAT TTAGGATGAA GGAACAAGG AAATATAGGG AAAAGTAGTA GACAAAAATTA V F I F K N L G . R K Q G N I G K S S R Q N .
>ABCA10.cDNA Protein	#5041	ACAAAAATCAG ACATGTTATT CATCCCAAC ATGGGTCTAT TTGTGCTTA AAAATAATTT AAAAATCATA Q N Q T C Y S S P T W V Y F V L K N N L K I I
>ABCA10.cDNA Protein	#5111	CAATATTAGG TTGGTTTCG GTTATTATCA ATAAAGCTAA CACTGAGAAC ATTTTACAAA TAAAAATATG Q Y . V G F R L L S I K L T L R T F Y K . K Y E
>ABCA10.cDNA Protein	#5181	AGTTTTTTAG CCTGAACCTC AAATGTATCA GCTATTTTIA AACATTATTT ACTCGGATTC TAAITTAATG F F S L N F K C I S Y F . T L F T R I L I . C
>ABCA10.cDNA Protein	#5251	TGACATTGAC TATAAGAAGG TCTGATAAAC TGATGAAATG GCACAGCATA ACATTTAATT ATAATGACAT D I D Y K K V . . T D E M A Q H N I . L . . H
>ABCA10.cDNA Protein	#5321	TCTGATTATA AAATAAATGC ATGTGAATTT TAGTACATAT TGAAGTTATA TGAAGAAGA TAGCCATAAT S D Y K I N A C E F . Y I L K L Y G R R . P . S
>ABCA10.cDNA Protein	#5391	CTGTAAGAAA GTACCGCAGT TAATATTTTC TTTAGCCAAC TTATATTCAA TGTATTTTTT ATGGATCCTT V R K Y R S . Y F L . P T Y I Q C I F Y G S F
>ABCA10.cDNA Protein	#5461	TTTCAAAGGT AGTATCAGTA GGCATAGTCA TTTTCIGTAT CTTTICACCT CACAGTTTCAAT GAACATTTC F K G S I S R H S H F L Y L F T S Q F M N I S
>ABCA10.cDNA Protein	#5531	CATGTCATTA TAGCACTTTT GTGTTATATA ATTGCTGCAT TAAAGTTATA GCTGTATTGA TGTAAATACCA H V I I A L L C Y I I A A L M L . L Y . C N T R

Fig. 31

>ABCA10.cDNA Protein	#5601	GAGTTGTTAC GTTGGGTTA TATGCAAGTT TATTTCTTAG AAATAAACT TTGATGGACT TTTAAAAAA V V T F G L Y A S L F L R N K T L M D F . K K
>ABCA10.cDNA Protein	#5671	AAAAAAAAA K K K

Fig. 3J

SEQUENCE LISTING

<110> Active Pass Pharamceuticals
 Le Bihan, Stephane
 Chen, Hongyun
 Kilinski, Ligia

<120> NOVEL ABCA10 TRANSPORTER AND USES
 THEREOF

<130> 100103.422PC

<140> PCT

<141> 2002-06-13

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 5680

<212> DNA

<213> Homo sapiens

<400> 1

```

gagataagcg tgcgtcaaca aattcaggct cttctgtaca agaattttct taaaaa:ttgg 60
agaataaaaa gagagtttat tggaatggac aataacattg tttctagggc tatattttgtg 120
catcttttcg gaacacttca gagctaccog ttttcctgaa caacctccta aagtcctggg 180
aagcgtggat cagtttaatg actctggcct ggtagtggca tatacaccag tcagtaacat 240
aacacaaagg ataatgaata agatggcctt ggcttccttt atgaaaggaa gaacagtcac 300
tgggacacca gatgaagaga ccatggatat agaacttcca aaaaaatacc atgaaatggg 360
gggagttata tttagtata ctttctcata tcgcctgaag ttttaattggg gatatagaat 420
cccagttata aaggagcact ctgaatacac agaacactgt tgggccatgc atggtgaaat 480
tttttgttac ttggcaaagt actggctaaa agggtttgta gcttttcaag ctgcaattaa 540
tgctgcaatt atagaagtca caacaaatca ttctgtaatg gaggagtga cgtcagttat 600
tggaataaat atgaagatac cacctttcat ttctaaggga gaaattatga atgaatgggt 660
tcattttact tgcttagttt ctttctcttc ttttatatac tttgcatcat taaatgttgc 720
aagggaaaga ggaaaattta agaaactgat gacagtaatg ggtctccgag agtcagcatt 780
ctggctctcc tggggattga catacatttg cttcatcttc attatgtcca tttttatggc 840
tctggtcata acatcaatct caattgtatt tcatactggc ttcattgtga tattcacact 900
ctatagctta tatggccttt ctttgatagc attggccttc ctcattgagt ttttaataag 960
gaaacctatg ctgcctggtt tggtctgatt tctcttcact gtattttggg gatgtctggg 1020
attcactgtg ttatacagac aacttccttt atctttggga tgggtattaa gtcttcttag 1080
cccttttgcc ttactgctg gaatggccca gattacacac ctggataatt acttaagtgg 1140
tgttattttt cctgatccct ctggggattc atacaaaatg atagccactt ttttcatttt 1200
ggcatttgat actcttttct atttgatatt cacattatat tttgagcgag ttttaccttc 1260
ctcattttgg tccaaacatc aaaatactca tcatgaaatc tttgagaatg aaataaatcc 1320
tgagcattcc tctgatgatt cttttgaacc ggtgtctcca gaattccatg gaaaagaagc 1380
cataagaatc agaatgtta taaaagaata taatggaaag actggaaaag tagaagcatt 1440
gcaaggcata ttttttgaca tatatgaagg acagatcact gcaatacttg ggcataatgg 1500
agctggtaaa tcaacactgc taaacattct tagtggaattg tctgtttcta cagaaggatc 1560
agccactatt tataatactc aactctctga aataactgac atggaagaaa ttagaaagaa 1620
tattggattt tgtccacagt tcaattttca atttgacttc ctcactgtga gagaaaacct 1680
cagggatttt gctaaaataa aagggtattc gccaaaggaa gtggaacaag aggtaaaaag 1740
aattataatg gaattagaca tgcaaagcat tcaagacatt attgctaaaa aattaagtgg 1800
tgggcagaag agaaaactaa cactagggat tgccatctta ggagatcctc aggttttgct 1860
gctagatgaa ccaactgctg gattggatcc cttttcaaga caccgagtgt ggagcctcct 1920

```

gaaggagcat	aaagtagacc	gacttatacct	cttcagtacc	caattcatgg	atgaggctga	1980
catcttggct	gataggaaag	tatttctgtc	taatgggaag	ttgaaatgtg	caggatcatc	2040
tttgttctg	aagcgaaagt	ggggatttgg	atatcattta	agtttacaca	ggaatgaaat	2100
gtgtgacaca	gaaaaaatca	catcccttat	taagcagcac	attcctgatg	ccaagttaac	2160
aacagaaagt	gaagaaaaac	ttgtatatag	tttgcctttg	gaaaaaacga	acaaatttcc	2220
agatctttac	agtgaccttg	ataagtgttc	tgaccagggc	ataaggaatt	atgctgtttc	2280
agtgacatct	ctgaatgaag	tattcttgaa	cctagaagga	aaatcagcaa	ttgatgaacc	2340
agattttgac	attgggaaac	aagagaaaat	acatgtgaca	agaaatactg	gagatgagtc	2400
tgaaatggaa	cagggttcttt	gttctcttcc	tgaacaaga	aaggctgtca	gtagtgcagc	2460
tctctggaga	cgacaaatct	atgcagtggc	aacacttcgc	ttcttaaagt	taaggcgtga	2520
aaggagagct	cttttgtgtt	tgttactagt	acttgggaatt	gcttttatcc	ccatcattct	2580
agagaagata	atgtataaag	taactcgtga	aactcattgt	tgggagtfff	caccagtat	2640
gtatttccct	tctctggaac	aaatcccgaa	gacgcctctt	accagcctgt	taatcgtaa	2700
taatacagga	tcaaatattg	aagacctcgt	gcattcactg	aagtgtcagg	atatagtttt	2760
ggaaatagat	gacttttagaa	acagaaatgg	ctcagatgat	ccctcctaca	atggagccat	2820
catagtgtct	ggtgaccaga	aggattacag	attttctgtt	gcgtgtaata	ccaagaaatt	2880
gaattgtttt	cctgttctta	tgggaattgt	tagcaatgcc	cttatgggaa	tttttaactt	2940
cacggagctt	attcaaacgg	agagcacttc	attttctcgt	gatgacatag	tgctggatct	3000
tggttttata	gatgggtcca	tatttttgtt	gttgatcaca	aactgcgttt	ctccttttat	3060
cggcatagat	agcatcagcg	attataaaaa	aaatgttcaa	tcccagttat	ggatttcagg	3120
ccctctggcct	tcagcatact	ggtgtggaca	ggctctggtg	gacattccat	tatacttctt	3180
gatttctctt	tcaatacatt	taatttacta	cttcataatt	ctgggattcc	agctttcatg	3240
ggaactcatg	tttgttttgg	tggatgcat	aattggttgt	gcagtttctc	ttatattcct	3300
cacatatgtg	ctttcattca	tctttcgcaa	gtggagaaaa	aataatggct	tttggctctt	3360
tggctttttt	attatcttaa	tatgtgtatc	cacaattatg	gtatcaactc	aatatgaaaa	3420
actcaactta	attttgtgca	tgattttcat	accttccctc	actttgctgg	ggtatgtcat	3480
gttattgatc	cagctcgact	ttatgagaaa	cttggacagt	ctggacaata	gaataaatga	3540
agtcaataaa	accattcttt	taacaacctt	aataccatac	cttcagagtg	ttattttcct	3600
ttttgtcata	aggtgtctgg	aaatgaagta	tggaaatgaa	ataatgaata	aagaccagct	3660
tttcagaatc	tctccacgga	gtagagaaac	tcatcccaat	ccggaagagc	ccgaagaaga	3720
agatgaagat	gttcaagctg	aaagagtcca	agcagcaa	gcactcactg	ctccaaactt	3780
ggaggaggaa	ccagtcataa	ctgcaagctg	tttacacaag	gaatattatg	agacaaaaga	3840
aaagtgcttt	tcaacaagaa	agaagaaaat	agccatcaga	aatgtttcct	tttgtgttaa	3900
aaaaggtgaa	gttttgggat	tactaggaca	caatggagct	ggtaaaagta	cttccattaa	3960
aatgataact	gggtgcacaa	agccaactgc	aggagtgggtg	gtgttacaa	gcagcagagc	4020
atcagtaagg	caacagcatg	acaacagcct	caagttcttg	gggtactgcc	ctcaggagaa	4080
ctcactgtgg	cccaagctta	caatgaaaga	gcacttggag	ttgtatgcag	ctgtgaaagg	4140
actgggcaaa	gaagatgctg	ctctcagtat	ttcacgattg	gtggaagctc	ttaagctcca	4200
ggaacaactt	aaggctcctg	tgaaaactct	atcagaggga	ataaagagaa	agctgtgctt	4260
tgtgttgagc	atcctgggga	acccatcagt	ggtgcttcta	gatgagccgt	tcaccgggat	4320
ggaccccag	gggcagcagc	aaatgtggca	gatacttcag	gctaccgtta	aaaacaagga	4380
gaggggcacc	ctcttgacca	cccattacat	gtcagaggct	gaggctgtgt	gtgaccgtat	4440
ggccatgatg	gtgtcaggaa	cgctaagggtg	tattggttcc	attcaacatc	tgaaaaacaa	4500
gtttggtaga	gattatttac	tagaaataaa	aatgaaagaa	cctaccagag	tggaagctct	4560
ccacacagag	attttgaagc	ttttcccaca	ggctgcttgg	caggaaagat	attcctcttt	4620
aatggcgat	aagttacctg	tggaggtgt	ccacctcta	tctcgggcct	ttttcaagtt	4680
agaggcgatg	aaacagacct	tcaacctgga	ggaatacagc	ctctctcagg	ctaccttgg	4740
gcaggtattc	ttagaactct	gtaaagagca	ggagctggga	aatgttgatg	ataaaattga	4800
tacaacagtt	gaatggaac	ttctcccaca	ggaagacctt	taaaatgaag	aacctcctaa	4860
cattcaattt	taggtcctac	tacattgtta	gtttccataa	ttctacaaga	atgtttcctt	4920
ttacttaagt	taacaaaaga	aaacatttaa	taaacattca	ataatgatta	cagttttcat	4980
ttttaaaaat	ttaggatgaa	ggaaacaagg	aaatataggg	aaaagtagta	gacaaaatta	5040
acaaaatcag	acatgttatt	catccccaac	atgggtctat	tttgtgctta	aaaataattt	5100
aaaaatcata	caatatttag	ttggttttcg	gttattatca	ataaagctaa	cactgagaac	5160
atttttacaa	taaaaatatg	agtttttttag	cctgaacttc	aatgtatca	gctattttta	5220
aacattattt	actcggattc	taatttaattg	tgacattgac	tataagaagg	tctgataaac	5280
tgatgaaatg	gcacagcata	acatttaatt	ataatgacat	tctgattata	aaataaatgc	5340
atgtgaattt	tagtacatat	tgaagttata	tggagaaga	tagccataat	ctgtaagaaa	5400

<400>	2															
Met	Asn	Lys	Met	Ala	Leu	Ala	Ser	Phe	Met	Lys	Gly	Arg	Thr	Val	Ile	
1				5					10					15		
Gly	Thr	Pro	Asp	Glu	Glu	Thr	Met	Asp	Ile	Glu	Leu	Pro	Lys	Lys	Tyr	
			20					25					30			
His	Glu	Met	Val	Gly	Val	Ile	Phe	Ser	Asp	Thr	Phe	Ser	Tyr	Arg	Leu	
		35					40					45				
Lys	Phe	Asn	Trp	Gly	Tyr	Arg	Ile	Pro	Val	Ile	Lys	Glu	His	Ser	Glu	
	50					55					60					
Tyr	Thr	Glu	His	Cys	Trp	Ala	Met	His	Gly	Glu	Ile	Phe	Cys	Tyr	Leu	
65					70					75					80	
Ala	Lys	Tyr	Trp	Leu	Lys	Gly	Phe	Val	Ala	Phe	Gln	Ala	Ala	Ile	Asn	
				85					90					95		
Ala	Ala	Ile	Ile	Glu	Val	Thr	Thr	Asn	His	Ser	Val	Met	Glu	Glu	Leu	
			100					105					110			
Thr	Ser	Val	Ile	Gly	Ile	Asn	Met	Lys	Ile	Pro	Pro	Phe	Ile	Ser	Lys	
		115					120						125			
Gly	Glu	Ile	Met	Asn	Glu	Trp	Phe	His	Phe	Thr	Cys	Leu	Val	Ser	Phe	
	130					135					140					
Ser	Ser	Phe	Ile	Tyr	Phe	Ala	Ser	Leu	Asn	Val	Ala	Arg	Glu	Arg	Gly	
145					150					155					160	
Lys	Phe	Lys	Lys	Leu	Met	Thr	Val	Met	Gly	Leu	Arg	Glu	Ser	Ala	Phe	
				165					170					175		
Trp	Leu	Ser	Trp	Gly	Leu	Thr	Tyr	Ile	Cys	Phe	Ile	Phe	Ile	Met	Ser	
		180						185					190			
Ile	Phe	Met	Ala	Leu	Val	Ile	Thr	Ser	Ile	Ser	Ile	Val	Phe	His	Thr	
		195					200					205				
Gly	Phe	Met	Val	Ile	Phe	Thr	Leu	Tyr	Ser	Leu	Tyr	Gly	Leu	Ser	Leu	
	210					215					220					
Ile	Ala	Leu	Ala	Phe	Leu	Met	Ser	Val	Leu	Ile	Arg	Lys	Pro	Met	Leu	
225					230					235					240	
Ala	Gly	Leu	Ala	Gly	Phe	Leu	Phe	Thr	Val	Phe	Trp	Gly	Cys	Leu	Gly	
				245					250					255		
Phe	Thr	Val	Leu	Tyr	Arg	Gln	Leu	Pro	Leu	Ser	Leu	Gly	Trp	Val	Leu	
		260						265					270			
Ser	Leu	Leu	Ser	Pro	Phe	Ala	Phe	Thr	Ala	Gly	Met	Ala	Gln	Ile	Thr	
		275					280					285				
His	Leu	Asp	Asn	Tyr	Leu	Ser	Gly	Val	Ile	Phe	Pro	Asp	Pro	Ser	Gly	
	290					295					300					
Asp	Ser	Tyr	Lys	Met	Ile	Ala	Thr	Phe	Phe	Ile	Leu	Ala	Phe	Asp	Thr	
305					310					315					320	
Leu	Phe	Tyr	Leu	Ile	Phe	Thr	Leu	Tyr	Phe	Glu	Arg	Val	Leu	Pro	Ser	
				325					330							

Glu	Ile	Asn	Pro	Glu	His	Ser	Ser	Asp	Asp	Ser	Phe	Glu	Pro	Val	Ser
		355					360					365			
Pro	Glu	Phe	His	Gly	Lys	Glu	Ala	Ile	Arg	Ile	Arg	Asn	Val	Ile	Lys
	370					375					380				
Glu	Tyr	Asn	Gly	Lys	Thr	Gly	Lys	Val	Glu	Ala	Leu	Gln	Gly	Ile	Phe
385					390					395					400
Phe	Asp	Ile	Tyr	Glu	Gly	Gln	Ile	Thr	Ala	Ile	Leu	Gly	His	Asn	Gly
				405					410					415	
Ala	Gly	Lys	Ser	Thr	Leu	Leu	Asn	Ile	Leu	Ser	Gly	Leu	Ser	Val	Ser
			420					425					430		
Thr	Glu	Gly	Ser	Ala	Thr	Ile	Tyr	Asn	Thr	Gln	Leu	Ser	Glu	Ile	Thr
		435					440						445		
Asp	Met	Glu	Glu	Ile	Arg	Lys	Asn	Ile	Gly	Phe	Cys	Pro	Gln	Phe	Asn
	450					455					460				
Phe	Gln	Phe	Asp	Phe	Leu	Thr	Val	Arg	Glu	Asn	Leu	Arg	Val	Phe	Ala
465					470					475					480
Lys	Ile	Lys	Gly	Ile	Gln	Pro	Lys	Glu	Val	Glu	Gln	Glu	Val	Lys	Arg
				485					490					495	
Ile	Ile	Met	Glu	Leu	Asp	Met	Gln	Ser	Ile	Gln	Asp	Ile	Ile	Ala	Lys
			500					505					510		
Lys	Leu	Ser	Gly	Gly	Gln	Lys	Arg	Lys	Leu	Thr	Leu	Gly	Ile	Ala	Ile
		515					520					525			
Leu	Gly	Asp	Pro	Gln	Val	Leu	Leu	Leu	Asp	Glu	Pro	Thr	Ala	Gly	Leu
	530					535					540				
Asp	Pro	Phe	Ser	Arg	His	Arg	Val	Trp	Ser	Leu	Leu	Lys	Glu	His	Lys
545					550					555					560
Val	Asp	Arg	Leu	Ile	Leu	Phe	Ser	Thr	Gln	Phe	Met	Asp	Glu	Ala	Asp
				565					570					575	
Ile	Leu	Ala	Asp	Arg	Lys	Val	Phe	Leu	Ser	Asn	Gly	Lys	Leu	Lys	Cys
			580					585					590		
Ala	Gly	Ser	Ser	Leu	Phe	Leu	Lys	Arg	Lys	Trp	Gly	Ile	Gly	Tyr	His
		595						600					605		
Leu	Ser	Leu	His	Arg	Asn	Glu	Met	Cys	Asp	Thr	Glu	Lys	Ile	Thr	Ser
	610					615					620				
Leu	Ile	Lys	Gln	His	Ile	Pro	Asp	Ala	Lys	Leu	Thr	Thr	Glu	Ser	Glu
625					630					635					640
Glu	Lys	Leu	Val	Tyr	Ser	Leu	Pro	Leu	Glu	Lys	Thr	Asn	Lys	Phe	Pro
				645					650					655	
Asp	Leu	Tyr	Ser	Asp	Leu	Asp	Lys	Cys	Ser	Asp	Gln	Gly	Ile	Arg	Asn
		660					665						670		
Tyr	Ala	Val	Ser	Val	Thr	Ser	Leu	Asn	Glu	Val	Phe	Leu	Asn	Leu	Glu
		675					680					685			
Gly	Lys	Ser	Ala	Ile	Asp	Glu	Pro	Asp	Phe	Asp	Ile	Gly	Lys	Gln	Glu
	690					695					700				
Lys	Ile	His	Val	Thr	Arg	Asn	Thr	Gly	Asp	Glu	Ser	Glu	Met	Glu	Gln
705					710					715					720
Val	Leu	Cys	Ser	Leu	Pro	Glu	Thr	Arg	Lys	Ala	Val	Ser	Ser	Ala	Ala
				725					730					735	
Leu	Trp	Arg	Arg	Gln	Ile	Tyr	Ala	Val	Ala	Thr	Leu	Arg	Phe	Leu	Lys
		740					745						750		
Leu	Arg	Arg	Glu	Arg	Arg	Ala	Leu	Leu	Cys	Leu	Leu	Leu	Val	Leu	Gly
		755					760					765			
Ile	Ala	Phe	Ile	Pro	Ile	Ile	Leu	Glu	Lys	Ile	Met	Tyr	Lys	Val	Thr
	770					775					780				
Arg	Glu	Thr	His	Cys	Trp	Glu	Phe	Ser	Pro	Ser	Met	Tyr	Phe	Leu	Ser
785					790					795					800
Leu	Glu	Gln	Ile	Pro	Lys	Thr	Pro	Leu	Thr	Ser	Leu	Leu	Ile	Val	Asn
				805					810					815	

Asn Thr Gly Ser Asn Ile Glu Asp Leu Val His Ser Leu Lys Cys Gln
 820 825 830
 Asp Ile Val Leu Glu Ile Asp Asp Phe Arg Asn Arg Asn Gly Ser Asp
 835 840 845
 Asp Pro Ser Tyr Asn Gly Ala Ile Ile Val Ser Gly Asp Gln Lys Asp
 850 855 860
 Tyr Arg Phe Ser Val Ala Cys Asn Thr Lys Lys Leu Asn Cys Phe Pro
 865 870 875 880
 Val Leu Met Gly Ile Val Ser Asn Ala Leu Met Gly Ile Phe Asn Phe
 885 890 895
 Thr Glu Leu Ile Gln Thr Glu Ser Thr Ser Phe Ser Arg Asp Asp Ile
 900 905 910
 Val Leu Asp Leu Gly Phe Ile Asp Gly Ser Ile Phe Leu Leu Leu Ile
 915 920 925
 Thr Asn Cys Val Ser Pro Phe Ile Gly Met Ser Ser Ile Ser Asp Tyr
 930 935 940
 Lys Lys Asn Val Gln Ser Gln Leu Trp Ile Ser Gly Leu Trp Pro Ser
 945 950 955 960
 Ala Tyr Trp Cys Gly Gln Ala Leu Val Asp Ile Pro Leu Tyr Phe Leu
 965 970 975
 Ile Leu Phe Ser Ile His Leu Ile Tyr Tyr Phe Ile Phe Leu Gly Phe
 980 985 990
 Gln Leu Ser Trp Glu Leu Met Phe Val Leu Val Val Cys Ile Ile Gly
 995 1000 1005
 Cys Ala Val Ser Leu Ile Phe Leu Thr Tyr Val Leu Ser Phe Ile Phe
 1010 1015 1020
 Arg Lys Trp Arg Lys Asn Asn Gly Phe Trp Ser Phe Gly Phe Phe Ile
 1025 1030 1035 1040
 Ile Leu Ile Cys Val Ser Thr Ile Met Val Ser Thr Gln Tyr Glu Lys
 1045 1050 1055
 Leu Asn Leu Ile Leu Cys Met Ile Phe Ile Pro Ser Phe Thr Leu Leu
 1060 1065 1070
 Gly Tyr Val Met Leu Leu Ile Gln Leu Asp Phe Met Arg Asn Leu Asp
 1075 1080 1085
 Ser Leu Asp Asn Arg Ile Asn Glu Val Asn Lys Thr Ile Leu Leu Thr
 1090 1095 1100
 Thr Leu Ile Pro Tyr Leu Gln Ser Val Ile Phe Leu Phe Val Ile Arg
 1105 1110 1115 1120
 Cys Leu Glu Met Lys Tyr Gly Asn Glu Ile Met Asn Lys Asp Pro Val
 1125 1130 1135
 Phe Arg Ile Ser Pro Arg Ser Arg Glu Thr His Pro Asn Pro Glu Glu
 1140 1145 1150
 Pro Glu Glu Glu Asp Glu Asp Val Gln Ala Glu Arg Val Gln Ala Ala
 1155 1160 1165
 Asn Ala Leu Thr Ala Pro Asn Leu Glu Glu Glu Pro Val Ile Thr Ala
 1170 1175 1180
 Ser Cys Leu His Lys Glu Tyr Tyr Glu Thr Lys Lys Ser Cys Phe Ser
 1185 1190 1195 1200
 Thr Arg Lys Lys Lys Ile Ala Ile Arg Asn Val Ser Phe Cys Val Lys
 1205 1210 1215
 Lys Gly Glu Val Leu Gly Leu Leu Gly His Asn Gly Ala Gly Lys Ser
 1220 1225 1230
 Thr Ser Ile Lys Met Ile Thr Gly Cys Thr Lys Pro Thr Ala Gly Val
 1235 1240 1245
 Val Val Leu Gln Gly Ser Arg Ala Ser Val Arg Gln Gln His Asp Asn
 1250 1255 1260
 Ser Leu Lys Phe Leu Gly Tyr Cys Pro Gln Glu Asn Ser Leu Trp Pro
 1265 1270 1275 1280

Lys Leu Thr Met Lys Glu His Leu Glu Leu Tyr Ala Ala Val Lys Gly
 1285 1290 1295
 Leu Gly Lys Glu Asp Ala Ala Leu Ser Ile Ser Arg Leu Val Glu Ala
 1300 1305 1310
 Leu Lys Leu Gln Glu Gln Leu Lys Ala Pro Val Lys Thr Leu Ser Glu
 1315 1320 1325
 Gly Ile Lys Arg Lys Leu Cys Phe Val Leu Ser Ile Leu Gly Asn Pro
 1330 1335 1340
 Ser Val Val Leu Leu Asp Glu Pro Phe Thr Gly Met Asp Pro Glu Gly
 1345 1350 1355 1360
 Gln Gln Gln Met Trp Gln Ile Leu Gln Ala Thr Val Lys Asn Lys Glu
 1365 1370 1375
 Arg Gly Thr Leu Leu Thr Thr His Tyr Met Ser Glu Ala Glu Ala Val
 1380 1385 1390
 Cys Asp Arg Met Ala Met Met Val Ser Gly Thr Leu Arg Cys Ile Gly
 1395 1400 1405
 Ser Ile Gln His Leu Lys Asn Lys Phe Gly Arg Asp Tyr Leu Leu Glu
 1410 1415 1420
 Ile Lys Met Lys Glu Pro Thr Gln Val Glu Ala Leu His Thr Glu Ile
 1425 1430 1435 1440
 Leu Lys Leu Phe Pro Gln Ala Ala Trp Gln Glu Arg Tyr Ser Ser Leu
 1445 1450 1455
 Met Ala Tyr Lys Leu Pro Val Glu Asp Val His Pro Leu Ser Arg Ala
 1460 1465 1470
 Phe Phe Lys Leu Glu Ala Met Lys Gln Thr Phe Asn Leu Glu Glu Tyr
 1475 1480 1485
 Ser Leu Ser Gln Ala Thr Leu Glu Gln Val Phe Leu Glu Leu Cys Lys
 1490 1495 1500
 Glu Gln Glu Leu Gly Asn Val Asp Asp Lys Ile Asp Thr Thr Val Glu
 1505 1510 1515 1520
 Trp Lys Leu Leu Pro Gln Glu Asp Pro
 1525

<210> 3
 <211> 5722
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (254)...(4885)

<400> 3
 gagataagcg tgcgtcaaca aattcaggct cttctgtaca agaattttct taaaaaatgg 60
 agaataaaaa gagagtttat tggaatggac aataacattg tttctagggc tatatttggtg 120
 catcttttcg gaacacttca gagctacccg ttttcctgaa caacctccta aagtcctggg 180
 aagcgtggat cagtttaatg actctggcct ggtagtggca tatacaccag tcagtaacat 240
 aacacaaagg ata atg aat aag atg gcc ttg gct tcc ttt atg aaa gga 289
 Met Asn Lys Met Ala Leu Ala Ser Phe Met Lys Gly
 1 5 10

aga aca gtc att ggg aca cca gat gaa gag acc atg gat ata gaa ctt 337
 Arg Thr Val Ile Gly Thr Pro Asp Glu Glu Thr Met Asp Ile Glu Leu
 15 20 25

cca aaa aaa tac cat gaa atg gtg gga gtt ata ttt agt gat act ttc 385
 Pro Lys Lys Tyr His Glu Met Val Gly Val Ile Phe Ser Asp Thr Phe

30	35	40	
tca tat cgc ctg aag ttt aat tgg gga tat aga atc cca gtt ata aag			433
Ser Tyr Arg Leu Lys Phe Asn Trp Gly Tyr Arg Ile Pro Val Ile Lys			
45	50	55	60
gag cac tct gaa tac aca gaa cac tgt tgg gcc atg cat ggt gaa att			481
Glu His Ser Glu Tyr Thr Glu His Cys Trp Ala Met His Gly Glu Ile			
	65	70	75
ttt tgt tac ttg gca aag tac tgg cta aaa ggg ttt gta gct ttt caa			529
Phe Cys Tyr Leu Ala Lys Tyr Trp Leu Lys Gly Phe Val Ala Phe Gln			
	80	85	90
gct gca att aat gct gca att ata gaa gtc aca aca aat cat tct gta			577
Ala Ala Ile Asn Ala Ala Ile Ile Glu Val Thr Thr Asn His Ser Val			
	95	100	105
atg gag gag ttg acg tca gtt att gga ata aat atg aag ata cca cct			625
Met Glu Glu Leu Thr Ser Val Ile Gly Ile Asn Met Lys Ile Pro Pro			
110	115	120	
ttc att tct aag gga gaa att atg aat gaa tgg ttt cat ttt act tgc			673
Phe Ile Ser Lys Gly Glu Ile Met Asn Glu Trp Phe His Phe Thr Cys			
125	130	135	140
tta gtt tct ttc tct tct ttt ata tac ttt gca tca tta aat gtt gca			721
Leu Val Ser Phe Ser Ser Phe Ile Tyr Phe Ala Ser Leu Asn Val Ala			
	145	150	155
agg gaa aga gga aaa ttt aag aaa ctg atg aca gta atg ggt ctc cga			769
Arg Glu Arg Gly Lys Phe Lys Lys Leu Met Thr Val Met Gly Leu Arg			
	160	165	170
gag tca gca ttc tgg ctc tcc tgg gga ttg aca tac att tgc ttc atc			817
Glu Ser Ala Phe Trp Leu Ser Trp Gly Leu Thr Tyr Ile Cys Phe Ile			
	175	180	185
ttc att atg tcc att ttt atg gct ctg gtc ata aca tca atc tca att			865
Phe Ile Met Ser Ile Phe Met Ala Leu Val Ile Thr Ser Ile Ser Ile			
190	195	200	
gta ttt cat act ggc ttc atg gtg ata ttc aca ctc tat agc tta tat			913
Val Phe His Thr Gly Phe Met Val Ile Phe Thr Leu Tyr Ser Leu Tyr			
205	210	215	220
ggc ctt tct ttg ata gca ttg gct ttc ctc atg agt gtt tta ata agg			961
Gly Leu Ser Leu Ile Ala Leu Ala Phe Leu Met Ser Val Leu Ile Arg			
	225	230	235
aaa cct atg ctc gct ggt ttg gct gga ttt ctc ttc act gta ttt tgg			1009
Lys Pro Met Leu Ala Gly Leu Ala Gly Phe Leu Phe Thr Val Phe Trp			
	240	245	250
gga tgt ctg gga ttc act gtg tta tac aga caa ctt cct tta tct ttg			1057
Gly Cys Leu Gly Phe Thr Val Leu Tyr Arg Gln Leu Pro Leu Ser Leu			
	255	260	265

gga tgg gta tta agt ctt ctt agc cct ttt gcc ttc act gct gga atg 1105
 Gly Trp Val Leu Ser Leu Leu Ser Pro Phe Ala Phe Thr Ala Gly Met
 270 275 280

gcc cag att aca cac ctg gat aat tac tta agt ggt gtt att ttt cct 1153
 Ala Gln Ile Thr His Leu Asp Asn Tyr Leu Ser Gly Val Ile Phe Pro
 285 290 295 300

gat ccc tct ggg gat tca tac aaa atg ata gcc act ttt ttc att ttg 1201
 Asp Pro Ser Gly Asp Ser Tyr Lys Met Ile Ala Thr Phe Phe Ile Leu
 305 310 315

gca ttt gat act ctt ttc tat ttg ata ttc aca tta tat ttt gag cga 1249
 Ala Phe Asp Thr Leu Phe Tyr Leu Ile Phe Thr Leu Tyr Phe Glu Arg
 320 325 330

gtt tta cct gat aaa gat ggc cat ggg gat tct cca tta ttt ttc ctt 1297
 Val Leu Pro Asp Lys Asp Gly His Gly Asp Ser Pro Leu Phe Phe Leu
 335 340 345

aag tcc tca ttt tgg tcc aaa cat caa aat act cat cat gaa atc ttt 1345
 Lys Ser Ser Phe Trp Ser Lys His Gln Asn Thr His His Glu Ile Phe
 350 355 360

gag aat gaa ata aat cct gag cat tcc tct gat gat tct ttt gaa ccg 1393
 Glu Asn Glu Ile Asn Pro Glu His Ser Ser Asp Asp Ser Phe Glu Pro
 365 370 375 380

gtg tct cca gaa ttc cat gga aaa gaa gcc ata aga atc aga aat gtt 1441
 Val Ser Pro Glu Phe His Gly Lys Glu Ala Ile Arg Ile Arg Asn Val
 385 390 395

ata aaa gaa tat aat gga aag act gga aaa gta gaa gca ttg caa ggc 1489
 Ile Lys Glu Tyr Asn Gly Lys Thr Gly Lys Val Glu Ala Leu Gln Gly
 400 405 410

ata ttt ttt gac ata tat gaa gga cag atc act gca ata ctt ggg cat 1537
 Ile Phe Phe Asp Ile Tyr Glu Gly Gln Ile Thr Ala Ile Leu Gly His
 415 420 425

aat gga gct ggt aaa tca aca ctg cta aac att ctt agt gga ttg tct 1585
 Asn Gly Ala Gly Lys Ser Thr Leu Leu Asn Ile Leu Ser Gly Leu Ser
 430 435 440

gtt tct aca gaa gga tca gcc act att tat aat act caa ctc tct gaa 1633
 Val Ser Thr Glu Gly Ser Ala Thr Ile Tyr Asn Thr Gln Leu Ser Glu
 445 450 455 460

ata act gac atg gaa gaa att aga aag aat att gga ttt tgt cca cag 1681
 Ile Thr Asp Met Glu Glu Ile Arg Lys Asn Ile Gly Phe Cys Pro Gln
 465 470 475

ttc aat ttt caa ttt gac ttc ctc act gtg aga gaa aac ctc agg gta 1729
 Phe Asn Phe Gln Phe Asp Phe Leu Thr Val Arg Glu Asn Leu Arg Val
 480 485 490

ttt gct aaa ata aaa ggg att cag cca aag gaa gtg gaa caa gag gta 1777
 Phe Ala Lys Ile Lys Gly Ile Gln Pro Lys Glu Val Glu Gln Glu Val

495	500	505	
aaa aga att ata atg gaa tta gac atg caa agc att caa gac att att Lys Arg Ile Ile Met Glu Leu Asp Met Gln Ser Ile Gln Asp Ile Ile 510 515 520			1825
gct aaa aaa tta agt ggt ggg cag aag aga aaa cta aca cta ggg att Ala Lys Lys Leu Ser Gly Gly Gln Lys Arg Lys Leu Thr Leu Gly Ile 525 530 535 540			1873
gcc atc tta gga gat cct cag gtt ttg ctg cta gat gaa cca act gct Ala Ile Leu Gly Asp Pro Gln Val Leu Leu Leu Asp Glu Pro Thr Ala 545 550 555			1921
gga ttg gat ccc ttt tca aga cac cga gtg tgg agc ctc ctg aag gag Gly Leu Asp Pro Phe Ser Arg His Arg Val Trp Ser Leu Leu Lys Glu 560 565 570			1969
cat aaa gta gac cga ctt atc ctc ttc agt acc caa ttc atg gat gag His Lys Val Asp Arg Leu Ile Leu Phe Ser Thr Gln Phe Met Asp Glu 575 580 585			2017
gct gac atc ttg gct gat agg aaa gta ttt ctg tct aat ggg aag ttg Ala Asp Ile Leu Ala Asp Arg Lys Val Phe Leu Ser Asn Gly Lys Leu 590 595 600			2065
aaa tgt gca gga tca tct ttg ttt ctg aag cga aag tgg ggt att gga Lys Cys Ala Gly Ser Ser Leu Phe Leu Lys Arg Lys Trp Gly Ile Gly 605 610 615 620			2113
tat cat tta agt tta cac agg aat gaa atg tgt gac aca gaa aaa atc Tyr His Leu Ser Leu His Arg Asn Glu Met Cys Asp Thr Glu Lys Ile 625 630 635			2161
aca tcc ctt att aag cag cac att cct gat gcc aag tta aca aca gaa Thr Ser Leu Ile Lys Gln His Ile Pro Asp Ala Lys Leu Thr Thr Glu 640 645 650			2209
agt gaa gaa aaa ctt gta tat agt ttg cct ttg gaa aaa acg aac aaa Ser Glu Glu Lys Leu Val Tyr Ser Leu Pro Leu Glu Lys Thr Asn Lys 655 660 665			2257
ttt cca gat ctt tac agt gac ctt gat aag tgt tct gac cag ggc ata Phe Pro Asp Leu Tyr Ser Asp Leu Asp Lys Cys Ser Asp Gln Gly Ile 670 675 680			2305
agg aat tat gct gtt tca gtg aca tct ctg aat gaa gta ttc ttg aac Arg Asn Tyr Ala Val Ser Val Thr Ser Leu Asn Glu Val Phe Leu Asn 685 690 695 700			2353
cta gaa gga aaa tca gca att gat gaa cca gat ttt gac att ggg aaa Leu Glu Gly Lys Ser Ala Ile Asp Glu Pro Asp Phe Asp Ile Gly Lys 705 710 715			2401
caa gag aaa ata cat gtg aca aga aat act gga gat gag tct gaa atg Gln Glu Lys Ile His Val Thr Arg Asn Thr Gly Asp Glu Ser Glu Met 720 725 730			2449

gaa cag gtt ctt tgt tct ctt cct gaa aca aga aag gct gtc agt agt Glu Gln Val Leu Cys Ser Leu Pro Glu Thr Arg Lys Ala Val Ser Ser 735 740 745	2497
gca gct ctc tgg aga cga caa atc tat gca gtg gca aca ctt cgc ttc Ala Ala Leu Trp Arg Arg Gln Ile Tyr Ala Val Ala Thr Leu Arg Phe 750 755 760	2545
tta aag tta agg cgt gaa agg aga gct ctt ttg tgt ttg tta cta gta Leu Lys Leu Arg Arg Glu Arg Arg Ala Leu Leu Cys Leu Leu Leu Val 765 770 775 780	2593
ctt gga att gct ttt atc ccc atc att cta gag aag ata atg tat aaa Leu Gly Ile Ala Phe Ile Pro Ile Ile Leu Glu Lys Ile Met Tyr Lys 785 790 795	2641
gta act cgt gaa act cat tgt tgg gag ttt tca ccc agt atg tat ttc Val Thr Arg Glu Thr His Cys Trp Glu Phe Ser Pro Ser Met Tyr Phe 800 805 810	2689
ctt tct ctg gaa caa atc ccg aag acg cct ctt acc agc ctg tta atc Leu Ser Leu Glu Gln Ile Pro Lys Thr Pro Leu Thr Ser Leu Leu Ile 815 820 825	2737
gtt aat aat aca gga tca aat att gaa gac ctc gtg cat tca ctg aag Val Asn Asn Thr Gly Ser Asn Ile Glu Asp Leu Val His Ser Leu Lys 830 835 840	2785
tgt cag gat ata gtt ttg gaa ata gat gac ttt aga aac aga aat ggc Cys Gln Asp Ile Val Leu Glu Ile Asp Asp Phe Arg Asn Arg Asn Gly 845 850 855 860	2833
tca gat gat ccc tcc tac aat gga gcc atc ata gtg tct ggt gac cag Ser Asp Asp Pro Ser Tyr Asn Gly Ala Ile Ile Val Ser Gly Asp Gln 865 870 875	2881
aag gat tac aga ttt tct gtt gcg tgt aat acc aag aaa ttg aat tgt Lys Asp Tyr Arg Phe Ser Val Ala Cys Asn Thr Lys Lys Leu Asn Cys 880 885 890	2929
ttt cct gtt ctt atg gga att gtt agc aat gcc ctt atg gga att ttt Phe Pro Val Leu Met Gly Ile Val Ser Asn Ala Leu Met Gly Ile Phe 895 900 905	2977
aac ttc acg gag ctt att caa acg gag agc act tca ttt tct cgt gat Asn Phe Thr Glu Leu Ile Gln Thr Glu Ser Thr Ser Phe Ser Arg Asp 910 915 920	3025
gac ata gtg ctg gat ctt ggt ttt ata gat ggg tcc ata ttt ttg ttg Asp Ile Val Leu Asp Leu Gly Phe Ile Asp Gly Ser Ile Phe Leu Leu 925 930 935 940	3073
ttg atc aca aac tgc gtt tct cct ttt atc ggc atg agc agc atc agc Leu Ile Thr Asn Cys Val Ser Pro Phe Ile Gly Met Ser Ser Ile Ser 945 950 955	3121
gat tat aaa aaa aat gtt caa tcc cag tta tgg att tca ggc ctc tgg Asp Tyr Lys Lys Asn Val Gln Ser Gln Leu Trp Ile Ser Gly Leu Trp	3169

960	965	970	
cct tca gca tac tgg tgt gga cag gct ctg gtg gac att cca tta tac			3217
Pro Ser Ala Tyr Trp Cys Gly Gln Ala Leu Val Asp Ile Pro Leu Tyr			
975	980	985	
ttc ttg att ctc ttt tca ata cat tta att tac tac ttc ata ttt ctg			3265
Phe Leu Ile Leu Phe Ser Ile His Leu Ile Tyr Tyr Phe Ile Phe Leu			
990	995	1000	
gga ttc cag ctt tca tgg gaa ctc atg ttt gtt ttg gtg gta tgc ata			3313
Gly Phe Gln Leu Ser Trp Glu Leu Met Phe Val Leu Val Val Cys Ile			
1005	1010	1015	1020
att ggt tgt gca gtt tct ctt ata ttc ctc aca tat gtg ctt tca ttc			3361
Ile Gly Cys Ala Val Ser Leu Ile Phe Leu Thr Tyr Val Leu Ser Phe			
1025	1030	1035	
atc ttt cgc aag tgg aga aaa aat aat ggc ttt tgg tct ttt ggc ttt			3409
Ile Phe Arg Lys Trp Arg Lys Asn Asn Gly Phe Trp Ser Phe Gly Phe			
1040	1045	1050	
ttt att atc tta ata tgt gta tcc aca att atg gta tca act caa tat			3457
Phe Ile Ile Leu Ile Cys Val Ser Thr Ile Met Val Ser Thr Gln Tyr			
1055	1060	1065	
gaa aaa ctc aac tta att ttg tgc atg att ttc ata cct tcc ttc act			3505
Glu Lys Leu Asn Leu Ile Leu Cys Met Ile Phe Ile Pro Ser Phe Thr			
1070	1075	1080	
ttg ctg ggg tat gtc atg tta ttg atc cag ctc gac ttt atg aga aac			3553
Leu Leu Gly Tyr Val Met Leu Leu Ile Gln Leu Asp Phe Met Arg Asn			
1085	1090	1095	1100
ttg gac agt ctg gac aat aga ata aat gaa gtc aat aaa acc att ctt			3601
Leu Asp Ser Leu Asp Asn Arg Ile Asn Glu Val Asn Lys Thr Ile Leu			
1105	1110	1115	
tta aca acc tta ata cca tac ctt cag agt gtt att ttc ctt ttt gtc			3649
Leu Thr Thr Leu Ile Pro Tyr Leu Gln Ser Val Ile Phe Leu Phe Val			
1120	1125	1130	
ata agg tgt ctg gaa atg aag tat gga aat gaa ata atg aat aaa gac			3697
Ile Arg Cys Leu Glu Met Lys Tyr Gly Asn Glu Ile Met Asn Lys Asp			
1135	1140	1145	
cca gtt ttc aga atc tct cca cgg agt aga gaa act cat ccc aat ccg			3745
Pro Val Phe Arg Ile Ser Pro Arg Ser Arg Glu Thr His Pro Asn Pro			
1150	1155	1160	
gaa gag ccc gaa gaa gaa gat gaa gat gtt caa gct gaa aga gtc caa			3793
Glu Glu Pro Glu Glu Glu Asp Glu Asp Val Gln Ala Glu Arg Val Gln			
1165	1170	1175	1180
gca gca aat gca ctc act gct cca aac ttg gag gag gaa cca gtc ata			3841
Ala Ala Asn Ala Leu Thr Ala Pro Asn Leu Glu Glu Glu Pro Val Ile			
1185	1190	1195	

act gca agc tgt tta cac aag gaa tat tat gag aca aag aaa agt tgc	3889
Thr Ala Ser Cys Leu His Lys Glu Tyr Tyr Glu Thr Lys Lys Ser Cys	
1200 1205 1210	
ttt tca aca aga aag aag aaa ata gcc atc aga aat gtt tcc ttt tgt	3937
Phe Ser Thr Arg Lys Lys Lys Ile Ala Ile Arg Asn Val Ser Phe Cys	
1215 1220 1225	
gtt aaa aaa ggt gaa gtt ttg gga tta cta gga cac aat gga gct ggt	3985
Val Lys Lys Gly Glu Val Leu Gly Leu Leu Gly His Asn Gly Ala Gly	
1230 1235 1240	
aaa agt act tcc att aaa atg ata act ggg tgc aca aag cca act gca	4033
Lys Ser Thr Ser Ile Lys Met Ile Thr Gly Cys Thr Lys Pro Thr Ala	
1245 1250 1255 1260	
gga gtg gtg gtg tta caa ggc agc aga gca tca gta agg caa cag cat	4081
Gly Val Val Val Leu Gln Gly Ser Arg Ala Ser Val Arg Gln Gln His	
1265 1270 1275	
gac aac agc ctc aag ttc ttg ggg tac tgc cct cag gag aac tca ctg	4129
Asp Asn Ser Leu Lys Phe Leu Gly Tyr Cys Pro Gln Glu Asn Ser Leu	
1280 1285 1290	
tgg ccc aag ctt aca atg aaa gag cac ttg gag ttg tat gca gct gtg	4177
Trp Pro Lys Leu Thr Met Lys Glu His Leu Glu Leu Tyr Ala Ala Val	
1295 1300 1305	
aaa gga ctg ggc aaa gaa gat gct gct ctc agt att tca cga ttg gtg	4225
Lys Gly Leu Gly Lys Glu Asp Ala Ala Leu Ser Ile Ser Arg Leu Val	
1310 1315 1320	
gaa gct ctt aag ctc cag gaa caa ctt aag gct cct gtg aaa act cta	4273
Glu Ala Leu Lys Leu Gln Glu Gln Leu Lys Ala Pro Val Lys Thr Leu	
1325 1330 1335 1340	
tca gag gga ata aag aga aag ctg tgc ttt gtg ttg agc atc ctg ggg	4321
Ser Glu Gly Ile Lys Arg Lys Leu Cys Phe Val Leu Ser Ile Leu Gly	
1345 1350 1355	
aac cca tca gtg gtg ctt cta gat gag ccg ttc acc ggg atg gac ccc	4369
Asn Pro Ser Val Val Leu Leu Asp Glu Pro Phe Thr Gly Met Asp Pro	
1360 1365 1370	
gag ggg cag cag caa atg tgg cag ata ctt cag gct acc gtt aaa aac	4417
Glu Gly Gln Gln Gln Met Trp Gln Ile Leu Gln Ala Thr Val Lys Asn	
1375 1380 1385	
aag gag agg ggc acc ctc ttg acc acc cat tac atg tca gag gct gag	4465
Lys Glu Arg Gly Thr Leu Leu Thr Thr His Tyr Met Ser Glu Ala Glu	
1390 1395 1400	
gct gtg tgt gac cgt atg gcc atg atg gtg tca gga acg cta agg tgt	4513
Ala Val Cys Asp Arg Met Ala Met Met Val Ser Gly Thr Leu Arg Cys	
1405 1410 1415 1420	
att ggt tcc att caa cat ctg aaa aac aag ttt ggt aga gat tat tta	4561
Ile Gly Ser Ile Gln His Leu Lys Asn Lys Phe Gly Arg Asp Tyr Leu	

```

1425      1430      1435
cta gaa ata aaa atg aaa gaa cct acc cag gtg gaa gct ctc cac aca 4609
Leu Glu Ile Lys Met Lys Glu Pro Thr Gln Val Glu Ala Leu His Thr
1440      1445      1450

gag att ttg aag ctt ttc cca cag gct gct tgg cag gaa aga tat tcc 4657
Glu Ile Leu Lys Leu Phe Pro Gln Ala Ala Trp Gln Glu Arg Tyr Ser
1455      1460      1465

tct tta atg gcg tat aag tta cct gtg gag gat gtc cac cct cta tct 4705
Ser Leu Met Ala Tyr Lys Leu Pro Val Glu Asp Val His Pro Leu Ser
1470      1475      1480

cgg gcc ttt ttc aag tta gag gcg atg aaa cag acc ttc aac ctg gag 4753
Arg Ala Phe Phe Lys Leu Glu Ala Met Lys Gln Thr Phe Asn Leu Glu
1485      1490      1495      1500

gaa tac agc ctc tct cag gct acc ttg gag cag gta ttc tta gaa ctc 4801
Glu Tyr Ser Leu Ser Gln Ala Thr Leu Glu Gln Val Phe Leu Glu Leu
1505      1510      1515

tgt aaa gag cag gag ctg gga aat gtt gat gat aaa att gat aca aca 4849
Cys Lys Glu Gln Glu Leu Gly Asn Val Asp Asp Lys Ile Asp Thr Thr
1520      1525      1530

ggt gaa tgg aaa ctt ctc cca cag gaa gac cct taa aatgaagaac 4895
Val Glu Trp Lys Leu Leu Pro Gln Glu Asp Pro *
1535      1540

ctcctaacat tcaatttttag gtccactact attgttagtt tccataattc tacaagaatg 4955
tttccttttta cttaagttaa caaaagaaaa catttaataa acattcaata atgattacag 5015
ttttcatttt taaaaattta ggatgaagga aacaaggaaa tatagggaag agtagtagac 5075
aaaattaaca aaatcagaca tgttattcat ccccaacatg ggtctatatt gtgcttaaaa 5135
ataatttaaa aatcatacaa tattagggtg gttttcgggtt attatcaata aagctaacac 5195
tgagaacatt ttacaaataa aaatatgagt ttttttagcct gaacttcaaa tgtatcagct 5255
atttttaaac attatttact cggatttctaa tttaatgtga cattgactat aagaaggctc 5315
gataaactga tgaaatggca cagcataaca ttttaattata atgacattct gattataaaa 5375
taaagcatg tgaatttttag tacatatgtga agttatatgg aagaagatag ccataatctg 5435
taagaaagta ccgcagttaa tattttcttt agccaactta tattcaatgt attttttatg 5495
gacccctttt caaaggtagt atcagtaggc atagtcattt tctgtatctt ttcacctcac 5555
agttcatgaa catttcccat gtcattatag cacttttgtg ttatataatt gctgcattaa 5615
tgttatagct gtattgatgt aataccagag ttgttacgtt tgggttatat gcaagtttat 5675
ttcttagaaa taaaactttg atggactttt aaaaaaaaaa aaaaaaa 5722

<210> 4
<211> 1543
<212> PRT
<213> Homo sapiens

<400> 4
Met Asn Lys Met Ala Leu Ala Ser Phe Met Lys Gly Arg Thr Val Ile
1 5 10 15
Gly Thr Pro Asp Glu Glu Thr Met Asp Ile Glu Leu Pro Lys Lys Tyr
20 25 30
His Glu Met Val Gly Val Ile Phe Ser Asp Thr Phe Ser Tyr Arg Leu
35 40 45
Lys Phe Asn Trp Gly Tyr Arg Ile Pro Val Ile Lys Glu His Ser Glu

```

50	55	60
Tyr Thr Glu His Cys Trp	Ala Met His Gly Glu	Ile Phe Cys Tyr Leu
65	70	75
Ala Lys Tyr Trp	Leu Lys Gly Phe Val	Ala Phe Gln Ala Ala Ile Asn
	85	90
Ala Ala Ile Ile Glu	Val Thr Thr Asn His Ser	Val Met Glu Glu Leu
	100	105
Thr Ser Val Ile Gly	Ile Asn Met Lys Ile Pro	Pro Phe Ile Ser Lys
	115	120
Gly Glu Ile Met Asn	Glu Trp Phe His Phe Thr	Cys Leu Val Ser Phe
	130	135
Ser Ser Phe Ile Tyr	Phe Ala Ser Leu Asn	Val Ala Arg Glu Arg Gly
145	150	155
Lys Phe Lys Lys Leu	Met Thr Val Met Gly	Leu Arg Glu Ser Ala Phe
	165	170
Trp Leu Ser Trp Gly	Leu Thr Tyr Ile Cys	Phe Ile Phe Ile Met Ser
	180	185
Ile Phe Met Ala Leu	Val Ile Thr Ser Ile Ser	Ile Val Phe His Thr
	195	200
Gly Phe Met Val Ile	Phe Thr Leu Tyr Ser	Leu Tyr Gly Leu Ser Leu
	210	215
Ile Ala Leu Ala Phe	Leu Met Ser Val Leu	Ile Arg Lys Pro Met Leu
225	230	235
Ala Gly Leu Ala Gly	Phe Leu Phe Thr Val	Phe Trp Gly Cys Leu Gly
	245	250
Phe Thr Val Leu Tyr	Arg Gln Leu Pro Leu	Ser Leu Gly Trp Val Leu
	260	265
Ser Leu Leu Ser Pro	Phe Ala Phe Thr Ala	Gly Met Ala Gln Ile Thr
	275	280
His Leu Asp Asn Tyr	Leu Ser Gly Val Ile	Phe Pro Asp Pro Ser Gly
290	295	300
Asp Ser Tyr Lys Met	Ile Ala Thr Phe Phe	Ile Leu Ala Phe Asp Thr
305	310	315
Leu Phe Tyr Leu Ile	Phe Thr Leu Tyr Phe	Glu Arg Val Leu Pro Asp
	325	330
Lys Asp Gly His Gly	Asp Ser Pro Leu Phe	Phe Leu Lys Ser Ser Phe
	340	345
Trp Ser Lys His Gln	Asn Thr His His Glu	Ile Phe Glu Asn Glu Ile
	355	360
Asn Pro Glu His Ser	Ser Asp Asp Ser Phe	Glu Pro Val Ser Pro Glu
	370	375
Phe His Gly Lys Glu	Ala Ile Arg Ile Arg	Asn Val Ile Lys Glu Tyr
385	390	395
Asn Gly Lys Thr Gly	Lys Val Glu Ala Leu	Gln Gly Ile Phe Phe Asp
	405	410
Ile Tyr Glu Gly Gln	Ile Thr Ala Ile Leu	Gly His Asn Gly Ala Gly
	420	425
Lys Ser Thr Leu Leu	Asn Ile Leu Ser Gly	Leu Ser Val Ser Thr Glu
	435	440
Gly Ser Ala Thr Ile	Tyr Asn Thr Gln Leu	Ser Glu Ile Thr Asp Met
	450	455
Glu Glu Ile Arg Lys	Asn Ile Gly Phe Cys	Pro Gln Phe Asn Phe Gln
465	470	475
Phe Asp Phe Leu Thr	Val Arg Glu Asn Leu	Arg Val Phe Ala Lys Ile
	485	490
Lys Gly Ile Gln Pro	Lys Glu Val Glu Gln	Glu Val Lys Arg Ile Ile
	500	505
Met Glu Leu Asp Met	Gln Ser Ile Gln Asp	Ile Ile Ala Lys Lys Leu

		515					520					525				
Ser	Gly	Gly	Gln	Lys	Arg	Lys	Leu	Thr	Leu	Gly	Ile	Ala	Ile	Leu	Gly	
	530					535					540					
Asp	Pro	Gln	Val	Leu	Leu	Leu	Asp	Glu	Pro	Thr	Ala	Gly	Leu	Asp	Pro	
545					550					555					560	
Phe	Ser	Arg	His	Arg	Val	Trp	Ser	Leu	Leu	Lys	Glu	His	Lys	Val	Asp	
				565					570					575		
Arg	Leu	Ile	Leu	Phe	Ser	Thr	Gln	Phe	Met	Asp	Glu	Ala	Asp	Ile	Leu	
			580					585					590			
Ala	Asp	Arg	Lys	Val	Phe	Leu	Ser	Asn	Gly	Lys	Leu	Lys	Cys	Ala	Gly	
		595					600					605				
Ser	Ser	Leu	Phe	Leu	Lys	Arg	Lys	Trp	Gly	Ile	Gly	Tyr	His	Leu	Ser	
	610					615					620					
Leu	His	Arg	Asn	Glu	Met	Cys	Asp	Thr	Glu	Lys	Ile	Thr	Ser	Leu	Ile	
625					630					635					640	
Lys	Gln	His	Ile	Pro	Asp	Ala	Lys	Leu	Thr	Thr	Glu	Ser	Glu	Glu	Lys	
				645					650					655		
Leu	Val	Tyr	Ser	Leu	Pro	Leu	Glu	Lys	Thr	Asn	Lys	Phe	Pro	Asp	Leu	
			660					665					670			
Tyr	Ser	Asp	Leu	Asp	Lys	Cys	Ser	Asp	Gln	Gly	Ile	Arg	Asn	Tyr	Ala	
		675					680					685				
Val	Ser	Val	Thr	Ser	Leu	Asn	Glu	Val	Phe	Leu	Asn	Leu	Glu	Gly	Lys	
	690					695					700					
Ser	Ala	Ile	Asp	Glu	Pro	Asp	Phe	Asp	Ile	Gly	Lys	Gln	Glu	Lys	Ile	
705					710					715					720	
His	Val	Thr	Arg	Asn	Thr	Gly	Asp	Glu	Ser	Glu	Met	Glu	Gln	Val	Leu	
				725					730					735		
Cys	Ser	Leu	Pro	Glu	Thr	Arg	Lys	Ala	Val	Ser	Ser	Ala	Ala	Leu	Trp	
			740					745					750			
Arg	Arg	Gln	Ile	Tyr	Ala	Val	Ala	Thr	Leu	Arg	Phe	Leu	Lys	Leu	Arg	
		755					760					765				
Arg	Glu	Arg	Arg	Ala	Leu	Leu	Cys	Leu	Leu	Leu	Val	Leu	Gly	Ile	Ala	
		770				775					780					
Phe	Ile	Pro	Ile	Ile	Leu	Glu	Lys	Ile	Met	Tyr	Lys	Val	Thr	Arg	Glu	
785					790					795					800	
Thr	His	Cys	Trp	Glu	Phe	Ser	Pro	Ser	Met	Tyr	Phe	Leu	Ser	Leu	Glu	
				805					810					815		
Gln	Ile	Pro	Lys	Thr	Pro	Leu	Thr	Ser	Leu	Leu	Ile	Val	Asn	Asn	Thr	
			820					825					830			
Gly	Ser	Asn	Ile	Glu	Asp	Leu	Val	His	Ser	Leu	Lys	Cys	Gln	Asp	Ile	
		835					840					845				
Val	Leu	Glu	Ile	Asp	Asp	Phe	Arg	Asn	Arg	Asn	Gly	Ser	Asp	Asp	Pro	
	850					855					860					
Ser	Tyr	Asn	Gly	Ala	Ile	Leu	Val	Ser	Gly	Asp	Gln	Lys	Asp	Tyr	Arg	
865					870											

980 985 990
 Phe Ser Ile His Leu Ile Tyr Tyr Phe Ile Phe Leu Gly Phe Gln Leu
 995 1000 1005
 Ser Trp Glu Leu Met Phe Val Leu Val Val Cys Ile Ile Gly Cys Ala
 1010 1015 1020
 Val Ser Leu Ile Phe Leu Thr Tyr Val Leu Ser Phe Ile Phe Arg Lys
 1025 1030 1035 1040
 Trp Arg Lys Asn Asn Gly Phe Trp Ser Phe Gly Phe Phe Ile Ile Leu
 1045 1050 1055
 Ile Cys Val Ser Thr Ile Met Val Ser Thr Gln Tyr Glu Lys Leu Asn
 1060 1065 1070
 Leu Ile Leu Cys Met Ile Phe Ile Pro Ser Phe Thr Leu Leu Gly Tyr
 1075 1080 1085
 Val Met Leu Leu Ile Gln Leu Asp Phe Met Arg Asn Leu Asp Ser Leu
 1090 1095 1100
 Asp Asn Arg Ile Asn Glu Val Asn Lys Thr Ile Leu Leu Thr Thr Leu
 1105 1110 1115 1120
 Ile Pro Tyr Leu Gln Ser Val Ile Phe Leu Phe Val Ile Arg Cys Leu
 1125 1130 1135
 Glu Met Lys Tyr Gly Asn Glu Ile Met Asn Lys Asp Pro Val Phe Arg
 1140 1145 1150
 Ile Ser Pro Arg Ser Arg Glu Thr His Pro Asn Pro Glu Glu Pro Glu
 1155 1160 1165
 Glu Glu Asp Glu Asp Val Gln Ala Glu Arg Val Gln Ala Ala Asn Ala
 1170 1175 1180
 Leu Thr Ala Pro Asn Leu Glu Glu Glu Pro Val Ile Thr Ala Ser Cys
 1185 1190 1195 1200
 Leu His Lys Glu Tyr Tyr Glu Thr Lys Lys Ser Cys Phe Ser Thr Arg
 1205 1210 1215
 Lys Lys Lys Ile Ala Ile Arg Asn Val Ser Phe Cys Val Lys Lys Gly
 1220 1225 1230
 Glu Val Leu Gly Leu Leu Gly His Asn Gly Ala Gly Lys Ser Thr Ser
 1235 1240 1245
 Ile Lys Met Ile Thr Gly Cys Thr Lys Pro Thr Ala Gly Val Val Val
 1250 1255 1260
 Leu Gln Gly Ser Arg Ala Ser Val Arg Gln Gln His Asp Asn Ser Leu
 1265 1270 1275 1280
 Lys Phe Leu Gly Tyr Cys Pro Gln Glu Asn Ser Leu Trp Pro Lys Leu
 1285 1290 1295
 Thr Met Lys Glu His Leu Glu Leu Tyr Ala Ala Val Lys Gly Leu Gly
 1300 1305 1310
 Lys Glu Asp Ala Ala Leu Ser Ile Ser Arg Leu Val Glu Ala Leu Lys
 1315 1320 1325
 Leu Gln Glu Gln Leu Lys Ala Pro Val Lys Thr Leu Ser Glu Gly Ile
 1330 1335 1340
 Lys Arg Lys Leu Cys Phe Val Leu Ser Ile Leu Gly Asn Pro Ser Val
 1345 1350 1355 1360
 Val Leu Leu Asp Glu Pro Phe Thr Gly Met Asp Pro Glu Gly Gln Gln
 1365 1370 1375
 Gln Met Trp Gln Ile Leu Gln Ala Thr Val Lys Asn Lys Glu Arg Gly
 1380 1385 1390
 Thr Leu Leu Thr Thr His Tyr Met Ser Glu Ala Glu Ala Val Cys Asp
 1395 1400 1405
 Arg Met Ala Met Met Val Ser Gly Thr Leu Arg Cys Ile Gly Ser Ile
 1410 1415 1420
 Gln His Leu Lys Asn Lys Phe Gly Arg Asp Tyr Leu Leu Glu Ile Lys
 1425 1430 1435 1440
 Met Lys Glu Pro Thr Gln Val Glu Ala Leu His Thr Glu Ile Leu Lys

1445 1450 1455
Leu Phe Pro Gln Ala Ala Trp Gln Glu Arg Tyr Ser Ser Leu Met Ala
1460 1465 1470
Tyr Lys Leu Pro Val Glu Asp Val His Pro Leu Ser Arg Ala Phe Phe
1475 1480 1485
Lys Leu Glu Ala Met Lys Gln Thr Phe Asn Leu Glu Glu Tyr Ser Leu
1490 1495 1500
Ser Gln Ala Thr Leu Glu Gln Val Phe Leu Glu Leu Cys Lys Glu Gln
1505 1510 1515 1520
Glu Leu Gly Asn Val Asp Asp Lys Ile Asp Thr Thr Val Glu Trp Lys
1525 1530 1535
Leu Leu Pro Gln Glu Asp Pro
1540